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STUDY OF ASSEMBLY AND FUNCTION OF THE DrrAB COMPLEX 
by 
Prajakta Pradhan 
Under the direction of Dr. Parjit Kaur 
ABSTRACT  
The DrrAB proteins of Streptomyces peucetius belong to the ABC family of ubiquitous 
membrane transporters. The DrrA and DrrB proteins together form a drug efflux pump that 
carries out the transport of the anticancer drug doxorubicin by carrying out ATP hydrolysis. The 
present study is the first where the intrinsic factors involved in the assembly of the DrrAB 
functional complex have been elucidated.   
The drrA and drrB genes in the wild type operon have overlapping stop and start codons 
(ATGA) which indicates translational coupling between the two genes.  On insertion of a 
fortuitous stop codon in DrrA it was shown that the expression of DrrB is coupled to that of the 
upstream gene drrA. Furthermore, it was observed that a functional complex could be achieved 
only when the genes were maintained in cis in a translationally coupled manner. Translational 
regulation in DrrA was found to be involved in the control of optimal levels of DrrB. Inhibitory 
interactions within drrA sequence were speculated to cause translational arrest at the C terminus 
of DrrA. A novel assembly domain that forms the interface between DrrA containing the 
Nucleotide Binding Domain (NBD) and DrrB comprising the TransMembrane Domain (TMD) 
was found.  
Based on the data presented in this study a model is proposed for the biogenesis of the 
DrrAB drug pump.  The model suggests that translational coupling between DrrA and DrrB is 
crucial for functional complex formation. Further, there is evidence of regulation of translation 
by attenuation in the intergenic region of drrA and drrB. The regulation seems to involve the last 
30 nucleotides of the mRNA of drrA and some upstream sequences within drrA that cause 
translational arrest within the C terminus of DrrA. Since DrrB is translationally coupled to drrA, 
this translational arrest in conjunction with coupling causes lowering in the levels of DrrB. 
Finally, since the DrrA-DrrB interaction domain lies in the C terminus of DrrA, only the fully 
translated DrrA product will be competent to form a complex with DrrB. This interaction 
between the C terminus of DrrA and the N terminus of DrrB may be crucial for initial targeting 
of the complex to the membrane. The model is expected to serve as primer and open up an 
interesting yet insufficiently understood subject of membrane protein biogenesis.  
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1 
INTRODUCTION 
 
 The soil bacterium, Streptomyces peucetius belongs to the class Actinobacteria and is the 
producer of antibiotics such as doxorubicin and daunorubicin [1]. The antibiotics are produced as 
secondary metabolites in response to environmental factors such as nutrient deprivation [2]. The 
DNR gene cluster contains both the biosynthesis and resistance genes for the antibiotics 
doxorubicin and daunorubicin [3]. The organism acquires self resistance to the drugs by 
expression of the drrAB genes located within the DNR operon [1].  
 The DrrAB proteins belong to the ABC family of membrane transporters.  DrrA is 
a peripheral membrane protein of about 36kDa and DrrB is an integral membrane protein 
(30kDa)[4]. They function together as a complex (Fig. I-1); which has been proposed to be 
consits of two subunits of DrrA and two subunits of DrrB[5].  The DrrA protein shows 36% 
identity and 54% similarity to the mammalian ABC transporter, ABC1; whereas DrrB belongs to 
the ABC-2 subfamily [6, 7].  Furthermore, the Nucleotide Binding Domain (NBD) of DrrA 
shows 29% identity and 47% similarity to NBD1 and NBD2 of P-glycoprotein (P-gp)[4]. Over-
expression of P-gp has been implicated to cause multiple drug resistance (MDR) which leads to 
chemotherapeutic failure in cancer cells [8]. P-gp is a single multidomain protein of about 170 
kDa with two NBDs and two TransMembrane Domains (TMD) as opposed to DrrAB where 
DrrA contains the NBD and DrrB comprises the TMD [4, 8]. Although the two are structurally 
diverse, their functional theme is common. P-gp confers resistance to doxorubicin, daunorubicin, 
and other drugs in cancer cells, whereas DrrAB confers resistance to doxorubicin and 
daunorubicin in the producer organism, Streptomyces peucetius[4, 8]. Thus the high homology 
and functional similarity to medically relevant drug transporters like ABC1 and P-gp makes the 
DrrAB system an ideal candidate for the study of assembly and function of drug pumps. The 
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broad aim of the current study was to understand the factors involved in the assembly of the drug 
efflux pump DrrAB. This laboratory has been involved in the characterization of the DrrAB 
efflux pump for the last several years and has gained important insights into both structure and 
function of this system. The initial studies involved sub-cloning of the drrAB operon into the 
heterologous host E.coli[4]. The proteins were shown to be stably expressed and to impart 
function in E.coli[4]. Biochemical studies showed that DrrA and DrrB were dependent on each 
other for function and stability[5]. DrrA was found to bind ATP only when DrrB was present, 
indicating that DrrA required DrrB to achieve an active conformation[5]. The DrrB protein was 
not seen when drrB was expressed from a plasmid by itself (Fig.I-3; lane 3)[5]. Stable protein 
expression of DrrB was however observed when expressed with DrrA either in cis (Fig.I-3; lane 
2)[5] or in trans (Fig.I-3; lane 5)[5]. Furthermore it was seen that overexpression of DrrB caused 
inhibition of cell growth whereas the growth physiology of cells containing DrrAB was 
unaffected (Fig.I-4)[4]. These data indicated that both DrrA and DrrB are interdependent on each 
other for function and stability. By gene fusion analysis, membrane topology of the DrrB protein 
was determined [9]. It was predicted to contain eight transmembrane domains with both the N- 
and the C- termini to lie in the cytoplasm [9]. Using chemical crosslinking studies the contact 
points between DrrA and DrrB were determined [10]. Based on this analysis DrrA was predicted 
to interact with both the N- and C- termini of DrrB [10].  Two models were proposed in the 
study. The first model speculated that one subunit of DrrA interacts with two subunits of DrrB 
simultaneously and the other hypothesized that one subunit of DrrA interacts with both the N- 
and C-termini of the same subunit of DrrB [10].  
Factors leading to the biogenesis of the DrrAB efflux pump had not been studied so far. 
An interesting observation that lead to the current study was noted during functional analysis of 
3 
the DrrAB proteins. It was observed that even though DrrA could rescue the expression of DrrB 
in both cis and trans, resistance to doxorubicin was conferred only when the two gene were 
expressed in cis [5]. This observation implied that DrrA and DrrB proteins form a functional 
complex only in the cis condition. In the wild type cis situation, the drrA and drrB genes are 
translationally coupled due to the overlap between the stop codon of drrA and the start codon of 
drrB.  Thus it was speculated that the cis location and translational coupling may be important 
factors for functional complex formation and were therefore investigated in Chapter one of this 
study.    
Proximity or overlap between the stop codon of one gene and start codon of the next in 
prokaryotic operons with polycistronic mRNA indicates translational coupling between the gene 
pair[11]. The translation of the downstream gene is thereby dependent on the active translation 
of the upstream gene[11]. The intergenic region between drrA and drrB is predicted to form a 
stem loop structure (ΔG = - 19.0 kcal/mol) which sequesters the Ribosome Binding Site (RBS) 
and start codon of drrB[12]. In translationally coupled systems dependency of expression arises 
due to occlusion of the Shine-Dalgarno (SD) and start codon within a stem loop structure [13, 
14]. The occluded SD and start codon become available only after the ribosomes primed to the 
translation of upstream sequences dissipate the secondary structure and allow access to the SD 
and start codon. This causes reinitiation and or de novo initiation of the translation of the 
downstream gene [15, 16].  
On placing the stop codon at the 71st amino acid in DrrA, the expression of DrrB was 
indeed shown to be translationally coupled to that of DrrA. On substitution of drrA with a gene 
unrelated to doxorubicin transport it was found that DrrB can be translationally coupled to any 
upstream ORF, but drrA is required to be present in the cis location for functional complex 
4 
formation.    In addition this study suggested that DrrA may play a role in controlling the 
expression levels of DrrB.   To investigate whether cis location of drrA and drrB is sufficient for 
complex formation, spacers of varying lengths were introduced between the two genes.   The 
importance of spatial proximity achieved via cis conformation has been shown to be an 
important factor in the functional assembly of the two domains IICGlc and IIBGlc of the glucose 
transporter of E.coli[17]. Although drrA and drrB are present in cis in the uncoupled constructs 
they were unable to confer doxorubicin resistance, indicating that both cis location and 
translational coupling are vital factors for functional complex formation. 
 A ten fold difference in the level of expression of DrrB was observed when it was 
coupled to another ORF, GeneX. This difference in the expression as compared to the wild type 
DrrAB cis system suggested that there was an intrinsic mechanism within DrrA that may be 
responsible for reduced levels of DrrB. The aim of Chapter 2 of the current study was to 
investigate of the mechanism(s) involved in regulation of DrrB levels. 
 The regulatory elements that could possibly cause reduction in the levels of DrrB 
include presence of rare codons in DrrA, mRNA processing, or regulation at the level of 
translation.  Expression in a heterologous system brings out the possibility of rare codons as a 
factor for reduced expression[18]. Complementation of rare codons in the heterologous host 
E.coli showed no change in DrrAB expression. Although mRNA processing has been suggested 
in controlling levels of expression it also did not seem to play a role in controlling DrrB levels in 
the DrrAB system. Regulation at the level of translation can occur either due to RNA interactions 
or can be protein-mediated[19]. RNA interactions result in negative regulation whereas protein-
mediated regulation may have a positive or negative effect on translation[19]. It appears that at 
least one mechanism for regulation of DrrB may be at the level of translation of DrrA.  The most 
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likely mechanism seems to involve an interaction between the last 30 base pairs of drrA and 
some upstream drrA sequences. This interaction may result in attenuation of DrrA translation, 
which through translational coupling may act to ensure optimum expression of DrrB.  A 
mechanism for involvement of the last ten amino acids of DrrA as well as translational coupling 
in assembly of the DrrAB complex is proposed in this study. The possibility of the involvement 
of other accessory proteins in the assembly of the complex cannot be ruled out and is currently 
under study. Recent data in this laboratory suggest that FtsH, an inner membrane protease, may 
be responsible for proteolysis of DrrB when DrrA is absent[20]. From the data available so far it 
can be concluded that DrrA binds to and protects DrrB from FtsH. It is however not known 
whether DrrA forms a complex with DrrB before or after it is targeted into the membrane. 
Additional data in this laboratory indicate that GroEL/ES also play a role in the assembly of the 
DrrAB complex[20].  Thus based on all the available data so far, it seems that the biogenesis of 
the DrrAB drug transporter depends on factors both intrinsic to the system (such as translational 
coupling) as well as external factors, including cellular proteases and chaperones.  
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Fig.I-1: Schematic representation of the DrrAB proteins  
  
 
 
 
 
 
Fig.I-2: Schematic representation of the clones pDx101, -102, and -103[5]. pDx101 shows the 
junction between drrA and drrB as it exists in the original operon. All three clones contain plac 
and the RBS of the arsA gene in front of the drrA or the drrB gene. pDx101 also contains the 
original RBS of the drrB gene within the coding sequence of drrA. Nucleotides ATGA at the 
beginning of drrB in pDx101 contain the start codon for DrrB and the stop codon for DrrA. 
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Fig. I-3: Effect of co-expression of DrrAB proteins[5] E. coli cells containing the indicated 
plasmids were induced with IPTG.  The cells were lysed by French press, followed by 
ultracentrifugation at 100,000 × g for 1hr to prepare membrane fractions.  25 µg of membrane 
protein was analyzed by SDS-PAGE on 12% gels, followed by Western Blot analysis using 
anti-DrrA (Panel A) or anti-DrrB (Panel B) antibodies. Lane 1, vector (pSU2718); lane 2, 
DrrAB (pDx101); lane 3, DrrA (pDx102); lane 4, DrrB (pDx103); lane 5, DrrA+DrrB 
(pDx108 + pDx103).    
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Fig. I-4: Effect of induction on ArsD-DrrA and ArsD-DrrB fusion proteins[4]. E.coli cells 
containing the indicated plasmids were grown to exponential phase and induced with 10 mM 
sodium arsenite. Growth was monitored by recording the OD600 of the cultures.  Δ, ArsD-DrrAB; 
°, ArsD-DrrA; •, ArsD-DrrB. 
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CHAPTER 1 
 
 
 
 
Role of Cis Expression and Translational Coupling in  
the Assembly of a Functional Drug Pump 
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ABSTRACT 
DrrAB proteins confer resistance to the commonly used anticancer drug, doxorubicin, in 
Streptomyces peucetius.  Since the DrrAB efflux pump is homologous to the human Multiple 
Drug Resistance (MDR) protein, P-glycoprotein (P-gp), the DrrAB system is expected to serve 
as a good model to understand the assembly and function of Pgp.  DrrA, the ATP binding 
subunit, and DrrB, the transmembrane subunit, have been previously shown to be biochemically 
coupled such that maintenance of DrrB in the cell depends on DrrA and the function of DrrA 
depends on the presence of DrrB.  Furthermore, drrA and drrB genes in the wild type operon 
have overlapping stop and start codons (ATGA). This overlap might indicate translational 
coupling between the two genes.  In the wild type system (when the genes are present in cis), the 
DrrA and DrrB proteins form a functional complex and impart resistance to the drug 
doxorubicin. Although the expression of DrrB can be rescued by expression of DrrA in trans the 
functional phenotype of doxorubicin resistance cannot be achieved.  The objective of this study 
was to understand the role of cis expression and translational coupling in the assembly of the 
DrrAB complex.  Insertion of a fortuitous stop codon in drrA sequence showed that expression 
of DrrB was indeed translationally coupled to the upstream ORF.  Although the expression of 
drrB could be coupled to any upstream ORF, drrA was required in the cis location for functional 
complex formation. Furthermore it was found that cis location of drrA and drrB is not sufficient 
for complex formation. Based on the observations, it is likely that the key to assembly of DrrAB 
lies in co-folding of the two protein components, which can be accomplished only by 
maintaining the genes in cis in a translationally coupled manner.  
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INTRODUCTION 
The soil bacterium, Streptomyces peucetius is the producer of the important 
chemotherapeutic compounds, doxorubicin and daunorubicin, and is itself resistant to the action 
of these cytotoxic agents[1].   The production of these antibiotics is triggered in the stationary 
phase in response to nutrient deprivation[2].   The DNR operon of Streptomyces peucetius 
consists of biosynthetic and resistance genes[3].   Both biosynthesis and resistance genes are 
turned on simultaneously in the stationary phase[2]. Resistance is conferred by the DrrA and 
DrrB proteins coded by the drrAB operon[4].   DrrA and DrrB have been envisioned to form an 
efflux pump that exports out the antibiotics doxorubicin and daunorubicin, thereby imparting 
resistance[4].   The drrAB operon has been subcloned into the heterologous host E.coli[4].   
DrrA and drrB genes have also been separately subcloned[4].   DrrA protein has been identified 
as a 36kDa peripheral membrane protein and DrrB as a 30kDa integral membrane protein[4].   
DrrA binds ATP in a doxorubicin-stimulated manner, thus it is expected to form the catalytic 
subunit[4].   The integral membrane component DrrB is likely to contain the drug binding 
domain and form the conduit for the export of doxorubicin[4].   The DrrA and DrrB proteins 
have been shown to be functional in E.coli as determined by doxorubicin resistance assays[4].   
Previous studies have shown that DrrA and DrrB proteins are biochemically coupled for their 
stability and function.   DrrA binds ATP only when DrrB is present indicating that DrrA requires 
DrrB to achieve an active conformation.   Further, DrrB protein is not detectable by Western 
blotting when drrB is expressed from a plasmid by itself.   When expressed with DrrA in a cis 
condition stable protein expression of DrrB is observed[5].   In the trans condition DrrA can also 
rescue the expression of DrrB to almost the same level as in the cis condition.   These and other 
data suggest that DrrB is translated by itself but is unstable in the absence of DrrA[5].   The 
12 
DrrAB efflux pump is homologous to P-glycoprotein[4, 8].   P-gp structurally consists of two 
nucleotide binding domains and two membrane spanning domains placed on a single large 
protein[8].   In contrast to P-gp, DrrA the nucleotide binding domain and DrrB the membrane 
spanning domain are separate subunits.    
DrrA and drrB genes in the wild type cis situation have overlapping stop and start codon 
(ATGA)[1].   This overlap indicates translational coupling between the two genes and was 
shown in the present study to be required for expression of DrrB.   Although the proteins can 
form a complex in the trans conformation and stabilize each other, functional complex is formed 
only when the two proteins are in cis[5].  Therefore, it is likely that the translational coupling 
between drrA and drrB is an important factor for functional complex formation.    
Translational coupling is a commonly observed regulatory control in prokaryotes with 
polycistronic mRNA[11]. In translationally coupled systems the downstream gene expression is 
dependent on active translation of the upstream gene. This strict control of expression may occur 
mainly due to the two possible reasons; a weak Shine Dalgarno (SD) or SD occluded within a 
stem loop structure [15, 16]. De novo initiation of translation would be almost impossible in both 
the scenarios and translation by upstream primed ribsomes would be obligatory. The role of 
translational coupling may be limited to controlling expression of downstream gene or may have 
additional implication on the function of the gene product.  The bacteriophage RNAs of the MS2 
and f1 family are some of the examples of general translational coupling[21, 22]. Several 
bacterial operons such as the galactose, spc rRNA, L-10 rRNA, alpha rRNA, atp and repAB 
have been extensively studied in context of translational coupling [13, 14, 23-26]. In the repAB 
operon repB is translationally coupled to repA. In this system it has been shown that coupling of 
repB to ANY upstream gene, not just repA, can restore the expression and function of repB.  
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Therefore in the repAB system the role of translational coupling is limited to controlling the 
expression of the downstream gene, repB[14].  Whereas in the atp operon which encodes for the 
H+-ATPase translational coupling plays a role in both the expression of the downstream gene and 
function of the protein encoded[23]. In the gene pair HA of the atp operon atpA is coupled to 
atpH.   AtpH encodes for the δ subunit which mediates binding of the F1 soluble fraction with the 
membrane bound F0 fraction of the complex[23]. The atpA gene product α is a part of a three 
subunit ATPase required for function[23]. Translational coupling therefore ensures that the δ 
binds the complex together followed immediately by the formation of the α subunit for ATPase 
subunit assembly[23]. The formation of the gene products of atpH and atpA therefore 
concomitantly links the steps of assembly of the H+-ATPase to the functional assembly of the 
complex[23]. The glucose transporter contains two subunits; IICBGlc and IIAGlc. The IICBGlc 
subunit consists of the hydrophobic domain IICGlc and the hydrophilic domain IIBGlc[17]. The 
two domains IICGlc and IIBGlc could be spilt by a 29 base linker containing an RBS and start 
codon at appropriate distance and could still impart function in cis but were non-functional when 
expressed in trans on separate plasmids[17]. The IICBGlc are therefore an example where spatial 
proximity was an important factor in functional complex formation. Translational coupling may 
act as a key regulatory control to ensure that the spatial proximity of the gene products is 
maintained for proper co-folding of the proteins. 
The present study focuses on the importance of translational coupling in functional 
complex formation in the DrrAB export system.   On substitution of drrA with a gene unrelated 
to doxorubicin transport it was found that DrrB can be translationally coupled to any upstream 
ORF, but drrA is required to be present in the cis location for functional complex formation.    In 
addition this study suggests that DrrA may act play a role in controlling the expression levels of 
14 
DrrB.   To investigate whether cis location of drrA and drrB is sufficient for complex formation, 
spacers of varying lengths were introduced between the two genes.   Although drrA and drrB are 
present in cis in these uncoupled constructs they were unable to confer doxorubicin resistance, 
indicating that both cis location and translational coupling is essential for functional complex 
formation. 
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MATERIALS AND METHODS 
Bacterial strains and plasmids.  The E. coli strains and plasmids used in this study are 
described in Table 1.1. 
Media and growth conditions.  The cells were grown in LB medium at 37°C.  M9 glucose 
medium was used where indicated.  Chloramphenicol was added to final concentration of 20 
μg/ml and Ampicillin was added to a final concentration of 100 μg/ml.  Doxorubicin was added 
at the indicated concentrations to test for resistance. 
DNA manipulations.  The conditions for plasmid isolation, DNA endonuclease restriction 
analysis, ligation, and sequencing have been described elsewhere [27]. 
Mutagenesis of the drrA gene to create a fortuitous stop in drrA.  The 10th nucleotide base 
(cytosine) of drrA was deleted in the plasmid pDx101 using a Strategene QuikChange multisite-
directed mutagenesis kit (La Jolla, CA).  Deletion of this base will produce a fortuitous stop in 
DrrA at the 71st amino acid.  The strategy involved the use of complementary primers that 
incorporated the change at the required position.  The nucleotide sequence of the primers used 
was UP-5’ ATGAACACGAGCCGACACGGG 3’, DN-5’CCCGTGTCGGCTCGTGTTTCAT 
3’.  The amplified product bearing the mutation was then transformed into XL1 blue competent 
cells (provided by the manufacturer) and plated on medium containing chloramphenicol.  
Plasmid DNA was isolated from the colonies, and the desired mutation in the drrA gene was 
verified by sequencing of DNA. Sequencing was carried out using ABI 377 or 3100 sequencers 
(Applied Biosystems) in the Core Facilities in the Department of Biology at the Georgia State 
University.  The resulting mutant was named pDx161 in this study.   
Substitution of drrA with geneX.  Strategene QuikChange multisite-directed mutagenesis kit 
(La Jolla, CA) was used to substitute three bases at position 963, 966 and 968 in drrA to 
16 
introduce an XhoI site.  The sequence of the primers used was UP-XhoI 5’ 
GCCGATGACCGCTCGAGGGAAGAAGCG3’, DN-XhoI 5’ 
CGCTTCTTCCCTCGAGCGGTCATCGGC3’.  The mutagenized clone was designated 
pDx137.  953 bases of arsA were amplified by polymerase chain reaction from the template 
pSU2718arsA.   The primers used contained the sequences for appropriate restriction sites.  The 
primers had the following nucleotide sequence,  
ArsA-NdeI-UP 5’ GGGAATTCCATATGCAATTCTTACAGAAT 3’, ArsA-XhoI-DN 
5’CCGCTCGAGCAACGCAGAAAGTGACGG 3’.  The 0.953 kilobase pair polymerase chain 
reaction amplified fragment of arsA was digested with NdeI and XhoI and ligated to pDx137 that 
had been digested with the same enzymes.  The resulting clone has been designated pDx150.  In 
pDx150, the arsA gene is followed by 33 bases of drrA which contain the wild type putative 
ribosome binding site of drrB.  Together the arsA (953bp) and drrA (33bp) sequence are 
referred to as geneX in this study.  In pDx150, geneX is translationally coupled to drrB, as in the 
wild type drrAdrrB operon. 
Translational Fusions of DrrB to β-Galactosidase.  A translational fusion of the first 15 amino 
acids of DrrB to the 8th amino acid of β-galactosidase was created.  Using pDx161 and pDx150 
as the template, the region containing the lac promoter and upto the 45th nucleotide of the drrB 
gene was polymerase chain reaction-amplified.  The primers had the following nucleotide 
sequence, and each primer contained a HindIII restriction site:  
UHAB 5’GCCGCCAAGCTTCCTCTCCCCGCGCGTTGG 3’; L15 5’ 
GCCGCCAAGCTTCGCTCACAGGGGTCGTGG 3’.  The amplified product was ligated to the 
translational fusion vector pMLB1069 that had been digested with HindIII[28].  Amplification 
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and subcloning of the fragment from pDx161 and pDx150 resulted in plasmid pDx163 and 
pDx151, respectively.           
Introduction of spacers between drrA and drrB.   Four spacers of varying lengths (3, 18, 41, 
68 base pairs respectively) were introduced between the stop codon of drrA and the start codon 
of drrB.  The three base spacer contained the sequence GGC and it was introduced by site-
directed mutagenesis (Stratagene) using the primers: 
UnTC-UP: 5’ GAGAAGGTGGCATGAGGCATGACGACGTCCCCCGGC 3’  
UnTC-DN: 5’ GCCGGGGGACGTCGTCATGCCTCATGCCACCTTCTC 3’.  The resulting 
clone with the 3bp spacer inserted between the stop of drrA and start of drrB is called pDx147.  
The other three spacers (17, 41, 68 base pairs respectively) were introduced such that the 
coupling sequence between drrA and drrB genes was disrupted and a non-coding nucleotide 
sequence was generated serving as spacers between them.  Each spacer also contained the 
putative ribosome binding site of drrB, is as present in the wild type operon.  The spacers were 
created using mutually primed synthesis to convert the single-stranded oligonucleotides to 
double stranded heteroduplex form [29].  To ensure that translation stops at the end of drrA, two 
stop codons were introduced in the primers.  The oligonucleotides were designed such that both 
the primers contained complementary sequences of about 10-20 bases in the middle of the 
primer.  The flanking regions contained XhoI and AatII restriction sites.  Briefly, the synthesis of 
spacers was carried out by mixing 100 μM each of the upstream and downstream primer, 
followed by incubation at 23°C for 2 h.  10 mM dNTPs and 10 U of the Large Klenow fragment 
were added to the primers and incubation was carried out at 23°C for 1 h.  Additional 10 U of the 
Large Klenow fragment was added to the above reaction and the reaction was allowed to 
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continue over night at 23°C in order to synthesize double stranded heteroduplex form of DNA.  
The following set of primers was used for the three spacers: 
Spacer1UP:5'GCCGATGACCGCTCGAGGGAAGAAGCGGCGGAAGAGGAGAAGGTGGC
ATAATAG3', 
Spacer1DN5'CGGGGGACGTCGTCATGCCTGCTTCTCCTCGGGCTATTATGCCACCTTCT
CCTC3', 
Spacer2UP5'GCCGATGACCGCTCGAGGGAAGAAGCGGCGGAAGAGGAGAAGGTGGC
ATAATAGCCCCAGAAACAATCT3', 
Spacer2DN5'CGGGGGACGTCGTCATGCCTGCTTCTCCTCGCCGTGGCTCGCAGATTGT
TTCTGGGGCTATTATGCCTCCTT3' 
Spacer3UP5'GCCGATGACCGCTCGAGGGAAGAAGCGGCGGAAGAGGAGAAGGTGGC
ATAATAGCCCCAGAAACAATCTGCGAGCCACGGCTTT3', 
Spacer3 DN 
5'CGGGGGACGTCGTCATGCCTGCTTCTCCTCGTTGACCCGGGCTTTAATCGTCGGAA
AGCCCTGGCTCGCAGATTGTTTCTGGGG 3'.  The synthesized fragments were digested 
with XhoI and AatII and then ligated to the vector pDx137 that had been digested with XhoI and 
AatII.  The resulting clones have been designated pDx197, pDx198 and pDx199.   
Growth and Expression.  E.coli TG1 or HMS174 cells containing the indicated plasmids were 
grown to mid-log phase and induced with 0.1 mM or 0.25 mM IPTG.  Growth was continued for 
an additional 3 h at 37°C.  The cells were spun down and lysed by a single passage through a 
French pressure cell at 20,000  p.s.i.  The cell lysates were centrifuged at 10,000 × g for 30 min 
to remove the unbroken cells.  The supernatants were fractionated into cytosolic and membrane 
fractions by ultrcentrifugation at 100,000 × g for 1h.     The membrane fractions were solubilized 
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in 4X Laemmli sample buffer by heating at 55°C for 10 min.  50 μg of membrane or cytosolic  
protein was analyzed by SDS-PAGE on 12% polyacrylamide gels, followed by Western blotting 
with either anti-DrrA or anti-DrrB antibodies.   
Measurement of β–Galactosidase activity.  The activity of the fusion proteins was determined 
by the methods published earlier[30].  Briefly, CC118 cells containing the fusion plasmid were 
grown to mid-log phase and induced with 0.25 mM IPTG for 3 h.  The cells were harvested and 
lysed by a single passage through a French pressure cell at 20,000 p.s.i.  The lysed cells were 
centrifuged at 10,000 × g for 30 min to remove unbroken cells.  100 μg of lysate was added to a 
tube containing 1 ml of Z buffer (60 mM Na2HPO4, 40 mM NaH2PO4, 10 mM KCl, 1 mM 
MgSO4, and 50 mM β-mercaptoethanol).  The tubes were placed into a 37 °C water bath.  The 
reaction was started by adding 0.1 ml of o-nitrophenyl-β-D-galactopyranoside (4 mg/ml in Z 
buffer) to each tube.  Reaction was stopped by adding 0.5 ml of 1 M Na2CO3 once sufficient 
yellow color was developed.  The color was analyzed spectrophotometrically at 420 and 550 nm.  
The β-galactosidase activity units were calculated [30]. 
Doxorubicin Resistance Assay.  Doxorubicin resistance assays were carried out on M9 plates 
supplemented with 0.25% casamino acids[27].  The plates were layered with 4 mL of top agar 
(0.8% agar in M9 medium) containing the desired concentration of doxorubicin.  Briefly, 4 mL 
of top agar containing 0, 4, 6, 8, or 10μg/mL of doxorubicin (Sigma Chemicals) and 1 mM 
Thiamine-HCl was poured on top of M9 plates.  The plates were covered with foil to prevent 
exposure to light.  A doxorubicin sensitive strain of E.coli, N43, was transformed with the 
indicated plasmids.  Freshly transformed N43 strains were grown for 8 h in 3 mL of LB with the 
appropriate antibiotics.  Two microliters of the 8 h old N43 culture from above was streaked on 
the plates containing doxorubicin.  N43 containing the plasmid pSU2718 was used as a negative 
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control.  The plates were then incubated at 37°C overnight, and growth was recorded after 24 h 
of incubation. 
mRNA secondary structure prediction. The drrAB gene sequence was analyzed using the 
mfold program developed by Zuker:  http://bioweb.pasteur.fr/seqanal/interfaces/mfold-
simple.html[12, 31]. The jpg. output file was analyzed for possible stem loop structures with 
significant energy. 
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RESULTS 
Functional phenotype achieved only in cis conformation. The DrrA and DrrB proteins in the 
wild type cis conformation confer resistance to doxorubicin in an E.coli strain, N43 that is 
sensitive to the drug doxorubicin.    Previous studies have indicated that DrrB is undetectable in 
the absence of DrrA.    DrrB can be rescued from degradation when drrA is brought on another 
plasmid in trans.    It was therefore important to determine if the trans conformation was 
functional.    The plasmids pDx108 and pDx103 bearing the drrA and drrB genes, respectively, 
were co-transformed into N43.    Control cells containing the plasmid pDx101 bearing the drrA 
and drrB genes in cis were able to impart resistance to doxorubicin; while the cells containing 
the drrA and drrB genes in trans were unable to impart function (Table 1.2).    This suggests that 
although the expression of drrB can be rescued in trans, a functional complex could be achieved 
only in the cis conformation.    The translational coupling between drrA and drrB may therefore 
be important in ensuring proper co-folding of the two proteins in cis. 
DrrB expression is translationally coupled to that of DrrA. To determine if translational 
coupling indeed plays a role in the expression of DrrB in the wild type operon, a fortuitous stop 
codon was introduced to ensure early termination of translation in DrrA.    Site-directed 
mutagenesis was used to create a fortuitous stop codon in drrA resulting in the clone pDx161 
(drrA*drrB).    The membrane fractions were analyzed by Western blotting using anti-DrrA and 
anti-DrrB serum.    Western blotting analysis using anti-DrrB serum showed that DrrB could be 
detected in the control cells containing pDx101 (Fig.1.1, Panel B; lane 2).    However, no DrrB 
could be detected in the membrane fraction prepared from cells containing pDx161 (Fig.1.1, 
Panel B; lane 5).    Since DrrA is known to restore the levels of DrrB in trans, pDx161 was co-
transformed with a plasmid containing the drrA gene.    No DrrB protein was seen (Fig.1.1, 
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Panel B; lane 7).   This indicates that DrrB was not translated from pDx161 clone, thus 
indicating that the translation of the drrB gene is dependent on the translation of the upstream 
gene drrA.    To determine the translation levels of DrrB in pDx161, a lacZ fusion to drrA*drrB 
(pDx163) was created.    The amount of DrrB translated from drrA*drrB::lacZ (pDx163) clone 
was 10-12 fold lower than the wild type (Fig.1.2).    The above data indicate that the expression 
of DrrB is dependent on DrrA.    Doxorubicin resistance assay showed that the cells containing 
pDx161 were sensitive to Dox, due to absence of the translated gene product (Table 1.3).    
Formation of RNA secondary structure in the intergenic region between drrA and drrB. 
The RNA secondary structure of the intergenic region formed by drrA and drrB was predicted 
by the mfold program. The intergenic region forms a stem loop with energy of -19.3 kcal 
(Fig.1.3). The RBS and the start codon of drrB are embedded within the stem loop and therefore 
may be unavailable for de novo priming of ribosomes. It is possible that actively translating 
upstream ribosomes can open up this secondary structure and initiate the translation of drrB. 
DrrB can be translationally coupled to any upstream ORF. To determine if the nature of the 
upstream gene was important for expression of DrrB, drrA was replaced by a gene unrelated to 
doxorubicin transport.    The geneXdrrB construct (pDx150) was constructed by replacing drrA 
with geneX.    The translational coupling sequence (ATGA) was maintained in the geneXdrrB 
construct.    The growth physiology of the cells containing pDx150 (geneXdrrB) was monitored 
after induction with IPTG.    Control cells containing the plasmid pDx101 (drrAdrrB) continued 
to grow after induction (Fig.1.4).    However, growth of cells containing pDx150 (geneXdrrB) 
was arrested upon induction with IPTG (Fig.1.4).    This indicated that high amounts of DrrB 
might be expressed from this clone causing inhibition and eventually leading to arrest in growth.    
The membrane fractions from cells containing pDx150 were analyzed by Western blotting using 
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anti-DrrA and anti-DrrB sera.    DrrB was seen in the control pDx101 containing cells, however 
no DrrB could be detected in the membrane fraction prepared from cells containing pDx150 
(Fig.1.5, Panel B; lane 4).    The absence of DrrB in this fraction was most likely due to the 
absence of DrrA.    Since DrrA restores the stability of DrrB in trans (Fig.1.5, Panel B; lane 3) 
drrA was brought in trans into cells containing pDx150.    Western blot analysis showed that a 
lot more DrrB was now detected as compared to the wild type cis situation (Fig.1.5, Panel B; 
lane 5).    These data suggest that not only can drrB expression be translationally coupled to any 
upstream ORF, but that DrrB expression is enhanced when drrA gene is substituted by another 
unrelated gene.   To determine the actual translation levels of DrrB, geneXdrrB::lacZ (pDx151) 
fusion was made.    An 8-12 fold increase in the amounts of DrrB from geneXdrrB was seen as 
compared to the wild type drrAdrrB (Fig.1.6).   Thus, Western blot and the lacZ fusion data are 
in agreement with the growth physiology observed in Fig.1.4.    These data indicate that in the 
wild type operon DrrA down regulates the expression of DrrB by an unknown mechanism.   
Since DrrB expressed from pDx150 was stabilized by DrrA expressed in trans, we wanted to 
determine if these two proteins now confer doxorubicin resistance.   Doxorubicin resistance 
assays showed that the trans combination of geneXdrrB and drrA failed to confer resistance 
(Table 1.4).   Thus DrrA could interact with DrrB to stabilize it but the resulting complex was 
non- functional.    This is consistent with results shown before where DrrA and DrrB expressed 
in trans do not confer dox resistance (Table 1.2).   Furthermore, when growth physiology of cells 
containing pDx150 (geneXdrrB) and drrA in trans was analyzed, growth was still seen to be 
inhibited (Fig. 1.4).   Thus, although DrrB was stabilized by DrrA, toxicity persisted; again 
suggesting that proper assembly of DrrA and DrrB did not occur. 
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Introduction of spacers between drrA and drrB uncouples the expression of the two genes. 
To determine if the overlap of stop codon of drrA and start codon of drrB in the wild type 
drrAB operon has any significance in maintaining proper functional conformation, spacers of 
varying lengths (3bp, 18bp, 41bp, or 68bp) were inserted between them, as described under 
Material and Methods of Chapter1.   All of these spacers separated the stop (drrA) and start 
(drrB) codons, however the 3 base pair spacer (pDx147) also increased the distance between the 
Shine Dalgarno and start codon of DrrB from 8 nucleotides in the wild type to 15 nucleotides in 
pDx147.   Western blot analysis showed that the amount of DrrB was drastically reduced in cells 
containing pDx147 (drrA-3bp-drrB) (Fig.1.7, Panel B; lane 6).   To determine the translation 
levels of DrrB in pDx147, lacZ fusion to drrA-3bp-drrB was created.    The amount of DrrB 
translated from drrA-3bp-drrB::lacZ (pDx178) clone was 23 fold lower than the wild type 
(pDx109) (Fig.1.8).    This decrease may be due to a change in the distance of the Shine 
Dalgarno sequence from the start codon, as mentioned above.   To avoid this, longer spacers 
containing the RBS at the right location were introduced.   The exact distance between the stop 
and start codon required for uncoupling is not known but it is thought that 30 bases are sufficient.   
Thus, we varied the length of the spacers from 18 base pairs to 68 base pairs and also inserted the 
Shine Dalgarno sequence within the spacers at exactly 8 bases upstream of the start codon of 
DrrB.   This was done to prevent deleterious effects of longer distance on expression of DrrB.   
Western blot analysis showed that the expression of DrrB is not compromised in these constructs 
where RBS of DrrB is provided at correct distance from the start codon, even though some 
variation in the amounts of DrrB was observed (Fig.1.9).   Interestingly, however, all of these 
constructs (containing spacers of different lengths) conferred doxorubicin sensitivity (Table 1.5).   
Since the protein expression levels are similar to those seen in the wild type, the doxorubicin 
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sensitive phenotype suggests that the cis location of drrA and drrB is not sufficient and that the 
coupled expression (overlap between the stop and start codons) of DrrA and DrrB is important 
for function.    
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DISCUSSION 
The present study aims to understand the role of translational coupling in the formation of 
the functional drug pump, DrrAB.  The DrrA and DrrB proteins have been previously shown to 
be dependent on each other for stability and function[5].  Although the two proteins were able to 
stabilize each other in trans, functional complex formation was observed only in the cis 
conformation.   In the wild type cis system the drrA and drrB genes have overlapping stop and 
start codons, indicating that the two genes may be translationally coupled.  The spatial proximity 
could be a key factor in ensuring proper co-folding for functional assembly of the two proteins in 
cis. 
In a translationally coupled system, translation of the downstream gene depends on the 
active translation of the upstream gene[11].  To test whether drrB is translationally coupled to 
drrA; a fortuitous stop codon was introduced in the drrA.  As a result the translation of drrA 
terminated at the 71st codon.  No DrrB protein expression was observed in absence of actively 
translating downstream gene drrA.  To verify whether DrrB was translated in absence of DrrA, a 
lacZ fusion was created.  The lacZ fusion data confirmed the expression results.  Therefore, it 
can be concluded that drrB is translationally coupled to drrA for its expression. 
One well studied mechanism for translational coupling depends on the formation of an 
RNA secondary structure, which sequesters the translational initiation region of the downstream 
gene. Therefore, de novo synthesis of the downstream gene by free ribosomes is inhibited [15, 
16].  By use of the mfold secondary structure prediction software, an RNA secondary structure 
with energy of – 19kcal/mol, predicted in the intergeneic region of drrA and drrB[12]. The RBS 
and start codon of drrB is embedded within this predicted stem loop structure.  Thus ribosomes 
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primed to carry out translation of DrrA may open up this secondary structure and allow access to 
the translation initiation region of DrrB.   
To determine if drrB expression could be coupled to any upstream gene, drrA was 
replaced by another gene, geneX.  The growth physiology of the cells containing geneXdrrB 
exhibited a growth inhibitory phenotype.  Over expression of membrane proteins is known to 
cause inhibition of growth.  The expression analysis revealed that the amount of DrrB in cells 
containing GeneXDrrB was significantly higher than DrrAB. The lacZ fusion showed 8-12 fold 
enhanced expression of DrrB from geneXdrrB as compared to the wild type drrAdrrB. This 
result was unexpected.  Although DrrA could interact with DrrB and stabilize it, the resulting 
complex was non-functional.  This further strengthens the hypothesis that spatial proximity 
achieved via translational coupling in the cis conformation aids in functional complex formation.  
The cause for high amounts of DrrB from GeneXDrrB as compared to DrrAB could be attributed 
to an unknown mechanism in DrrA that causes down regulation in the wild type DrrAB system.    
To determine whether cis location of the genes was sufficient for complex formation, 
spacers of varying lengths were inserted between drrA and drrB.  Insertion of 3 bases between 
drrA and drrB significantly decreased the expression of drrB.  The optimal distance between the 
Shine Dalgarno sequence and start codon is 8 bases[32].  This was changed to 15 bases on 
insertion of the 3 base spacer, which may be responsible for the reduced expression of DrrB.  
Longer spacers containing the RBS at the right location were introduced.   Although expression 
analysis showed that the level of DrrA and DrrB was similar to wild type levels, interestingly, all 
of these constructs (containing spacers of different lengths) conferred doxorubicin sensitivity.  
This suggests that the cis location of drrA and drrB is not sufficient and that the coupled 
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expression (overlap between the stop and start codons) of DrrA and DrrB is important for 
function.  
 The phenomenon of translational coupling has been well studied in many systems in 
context of regulation of gene expression. The role of translational coupling in function has been 
reported before. In the atp operon the translational coupling between the gene pair H and A 
ensures that the gene product of atpH (δ) which binds cytosolic and membrane fraction is formed 
before the assembly of the ATPase subunit, thereby linking the steps of assembly to 
function[23]. Role of spatial proximity in functional complex formation has been noted in the 
IICBGlc subunit of the glucose transporter of E.coli[17]. Thus the present study implicates that 
translational coupling plays a role in function of the DrrAB efflux pump by ensuring spatial 
proximity which helps in proper co-folding of the two proteins as shown in the model (Fig.D-1). 
 
 
Fig.D-1: A proposed model for the assembly of DrrAB proteins via translational coupling. 
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Table 1.1: Bacterial strains and plasmids 
 
 
Strains and, plasmids  
Strains or 
plasmids 
 
Genotype or description Reference 
or source 
Strains   
CC118 F-araD139_(ara-leu)7697_lacX74_phoAD20galK16 thi rpsE rpoB 
argE(Am) recA1 
[33] 
TG1 K-12 D(lac-pro) supE thi hsdD5/F9 tra36 proA1B1 lacIq lacZDM15 [27] 
N43 ara-14 Dlac-85 acrA1 supE44? galK2 rpsL197 malA1 (lr) xyl-5 mtl-1 [34] 
XL-1Blue recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F´ proAB 
lacIqZΔM15 Tn10 (Tetr)] 
[27] 
HMS174 K-12 F- recA1 hsdR(rK12- mK12+) (Rif R) [27] 
Plasmids   
pDx101 PlacdrrAB in pSU2718 [4] 
pDx102 PlacdrrA in pSU2718 [4] 
pDx103 PlacdrrB in pSU2718 [4] 
pDx108 PlacdrrA in pUC18 [5] 
pDx109 PlacdrrA-drrBfirst45nts-lacZ fusion [5] 
pDx110 PlacdrrBfirst45nts-lacZ fusion [5] 
pDx147 PlacdrrA-3bp-drrB in pSU2718 This study 
pDx150 PlacarsAfirst953nts-drrAlast33nts-drrB in pSU2718 This study 
pDx151 PlacarsAfirst953nts-drrAlast33nts-drrBfirst45nts-lacZ fusion 
(LacZ fused to 15th amino acid in drrB in pMLB1069) 
This study 
pDx161 PlacdrrA-Δ10thnt-drrB in pSU2718 This study 
pDx163 PlacdrrA-Δ10thnt –drrBfirst45nts-LacZ in pMLB1069 This study 
pDx178 PlacdrrA-3bp-drrBfirst45nts-lacZ fusion in pMLB1069 This study 
pDx197 PlacdrrA-XhoI site introduced before drrA stop-17bp spacer-drrB in 
pSU2718  
This study 
pDx198 PlacdrrA-XhoI site introduced before drrA stop-41bp spacer-drrB in 
pSU2718  
This study 
pDx199 PlacdrrA-XhoI site introduced before drrA stop-68bp spacer-drrB in 
pSU2718  
This study 
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Table 1.2: Doxorubicin Resistance of E.coli N43 cells expressing DrrA and DrrB proteins 
in the cis and trans conformation.  N43 cells containing indicated plasmids were plated on 
M9 plates containing different concentrations of doxorubicin.  The plates were incubated at 
37oC. Growth was scored after 24 hours of incubation.  Legend: +++, very good growth; ++, 
good growth; +, some growth; -, no growth. 
Amount of Dox, µg/ml Plasmid in N43 
No dox 4μg/ml 6 μg/ml 8μg/ml 10μg/ml 
Vector (pSU2718) +++ ++ - - - 
DrrA (pDx108) +++ - - - - 
DrrB (pDx103) +++ ++ - - - 
DrrAB (pDx101) +++ +++ +++ ++ ++ 
DrrA+DrrB (pDx108+pDx103) +++ - - - - 
Legend: +++, very good growth; ++, good growth; +, some growth;-, no growth. 
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Table 1.3: Doxorubicin Resistance of E.coli N43 cells containing a fortuitous stop in DrrA.  
N43 cells containing indicated plasmids were plated on M9 plates containing different 
concentrations of doxorubicin.  The plates were incubated at 37oC. Growth was scored after 24 
hours of incubation.  Legend: +++, very good growth; ++, good growth; +, some growth; -, no 
growth. 
Amount of Dox, µg/ml Plasmid in N43 
No dox 4μg/ml 6 μg/ml 8μg/ml 10μg/ml
Vector (pSU2718) +++ ++ - - - 
DrrA (pDx108) +++ - - - - 
DrrB (pDx103) +++ ++ - - - 
DrrAB (pDx101) +++ +++ +++ ++ ++ 
DrrA+DrrB (pDx108+pDx103) +++ - - - - 
DrrA*DrrB (pDx161) +++ - - - - 
DrrA*DrrB + DrrA (pDx161+pDx108) +++ - - - - 
Legend: +++, very good growth; ++, good growth; +, some growth;-, no growth. 
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Table 1.4: Doxorubicin Resistance of E.coli N43 cells expressing GeneXDrrB and 
GeneXDrrB with DrrA in trans.  N43 cells containing indicated plasmids were plated on M9 
plates containing different concentrations of doxorubicin.  The plates were incubated at 37oC. 
Growth was scored after 24 hours of incubation.  Legend: +++, very good growth; ++, good 
growth; +, some growth; -, no growth. 
Amount of Dox, µg/ml Plasmid in N43 
No dox 4μg/ml 6 μg/ml 8μg/ml 10μg/ml
Vector (pSU2718) +++ ++ - - - 
DrrA (pDx108) +++ - - - - 
DrrB (pDx103) +++ ++ - - - 
DrrAB (pDx101) +++ +++ +++ ++ ++ 
DrrA+DrrB (pDx108+pDx103) +++ - - - - 
GeneXDrrB (pDx150) +++ - - - - 
GeneXDrrB+DrrA (pDx150+pDx108) +++ - - - - 
Legend: +++, very good growth; ++, good growth; +, some growth;-, no growth. 
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Table 1.5: Doxorubicin Resistance of E.coli N43 cells expressing DrrA and DrrB with 
spacers between them.  N43 cells containing indicated plasmids were plated on M9 plates 
containing different concentrations of doxorubicin.  The plates were incubated at 37oC. Growth 
was scored after 24 hours of incubation.  Legend: +++, very good growth; ++, good growth; +, 
some growth; -, no growth. 
Amount of Dox, µg/ml Plasmid in N43 
No dox 4μg/ml 6 μg/ml 8μg/ml 10μg/ml 
Vector (pSU2718) +++ ++ - - - 
DrrA (pDx108) +++ - - - - 
DrrB (pDx103) +++ ++ - - - 
DrrAB (pDx101) +++ +++ +++ ++ ++ 
DrrA+DrrB (pDx108+pDx103) +++ - - - - 
DrrA-3bp-DrrB (pDx147) +++ - - - - 
DrrA-17bp-DrrB (pDx197) +++ ++ - - - 
DrrA-41bp-DrrB (pDx198) +++ ++ - - - 
DrrA-68bp-DrrB (pDx199) +++ ++ - - - 
Legend: +++, very good growth; ++, good growth; +, some growth;-, no growth. 
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I      II 
 
Fig.1.1: Effect of fortuitous stop in drrA on the expression levels of DrrA and DrrB.  I, 
Schematic representation of the clone pDx161 shows the stop codon in drrA. The un-translated 
region within drrA contains the RBS of drrB. II, E. coli cells containing the indicated plasmids 
were induced with IPTG.  The cells were lysed by French press, followed by 
ultracentrifugation at 100,000 × g for 1hr to prepare membrane fractions.  25 µg of membrane 
protein was analyzed by SDS-PAGE on 12% gels, followed by Western Blot analysis using 
anti-DrrA (Panel A) or anti-DrrB (Panel B) antibodies. Lane 1, vector (pSU2718); lane 2, 
DrrAB (pDx101); lane 3, DrrA (pDx102); lane 4, DrrB (pDx103); lane 5, DrrA*DrrB 
(pDx161) ; lane 6, DrrA+DrrB (pDx108 + pDx103) ; lane 7, DrrA*DrrB+DrrA (pDx161 + 
pDx108).   
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Fig.1.2: Schematic representation of the translational fusions of DrrB (pDx101 and 
pDx161) to β-galactosidase (pDx109 and pDx163) and their activities. The first 15 amino 
acids of the DrrB protein were fused to β-galactosidase as described under “Materials and 
Methods.” pDx109 and pDx163 are derived from pDx101 and pDx161, respectively. β-
Galactosidase activity of the fusion proteins encoded by pDx109 and pDx163 is shown on the 
right in Miller units/mg of total cell protein. 
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Fig.1.3: Predicted RNA secondary structure between the intergenic region of drrA and 
drrB [31]. Secondary structure was predicted by the mfold program obtained on the RNA 
mfold version 2.3 server (http://frontend.bioinfo.rpi.edu/applications/mfold/cgi-bin/rna-
form1.cgi).  RBS and start codon of DrrB have been indicated. The predicted energy of the 
secondary structure is also indicated.  
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Fig.1.4: Effect of expression of GeneXDrrB on the growth phenotype of E.coli cells. E.coli 
containing the indicated plasmids were grown to mid-log phase and induced with 0.1 mM IPTG. 
Growth was monitored for 3 h at 37°C after induction with IPTG. , Vector (pSU 2718); 
, DrrAB (pDx101); , DrrA + DrrB (pDx108 + pDx103); , GeneXDrrB 
(pDx150); ,GeneXDrrB+DrrA (pDx150 + pDx108).  
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I      II  
 
Fig.1.5: Gene substitution of drrA with geneX: effect on expression of DrrB. I, Schematic 
representation of the clones pDx101 (drrAdrrB) and pDx150 (geneXdrrB). The clones contain 
plac and the RBS in front of drrA or geneX. GeneX contains the last 30 bases of drrA with the 
original RBS of the drrB gene embedded within it and the translational coupling sequence 
ATGA. II, E. coli cells containing the indicated plasmids were induced with IPTG.  The cells 
were lysed by French press, followed by ultracentrifugation at 100,000 × g for 1hr to prepare 
membrane fractions.  25 µg of membrane protein was analyzed by SDS-PAGE on 12% gels, 
followed by Western Blot analysis using anti-DrrA (Panel A) or anti-DrrB (Panel B) 
antibodies. Lane 1, vector (pSU2718); lane 2, DrrAB (pDx101); lane 3, DrrA+DrrB (pDx108 + 
pDx103) ; lane 4, GeneXDrrB (pDx150); lane 5, GeneXDrrB+DrrA  (pDx150 + pDx108).   
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Fig.1.6: Schematic representation of the translational fusions of DrrB (pDx101 and 
pDx150) to β-galactosidase (pDx109 and pDx151) and their activities. The first 15 amino 
acids of the DrrB protein were fused to β-galactosidase as described under “Materials and 
Methods.” pDx109 and pDx151 are derived from pDx101 and pDx150, respectively. β-
Galactosidase activities of the fusion proteins encoded by pDx109 and pDx151 are shown on the 
right in Miller units/mg of total cell protein. 
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Fig.1.7: Effect of 3 base pair spacer on the expression of DrrB protein. I, Schematic 
representation of the clones pDx101 (drrAdrrB) and pDx147 (drrA-3bp-drrB). The clone 
pDx147 contains 3 base pairs (GGC) between the stop codon of DrrA and start codon of DrrB. 
II, E. coli cells containing the indicated plasmids were induced with IPTG.  The cells were 
lysed by French press, followed by ultracentrifugation at 100,000 × g for 1hr to prepare 
membrane fractions.  25 µg of membrane protein was analyzed by SDS-PAGE on 12% gels, 
followed by Western Blot analysis using anti-DrrA (Panel A) or anti-DrrB (Panel B) 
antibodies. Lane 1, vector (pSU2718); lane 2, DrrA (pDx102);  lane 3, DrrB (pDx103); lane 4, 
DrrAB (pDx101); lane 5, DrrA+DrrB (pDx108 + pDx103) ; lane 6, DrrA-3bp-DrrB (pDx147).   
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Fig.1.8: Schematic representation of the translational fusions of DrrB (pDx101 and 
pDx147) to β-galactosidase (pDx109 and pDx178) and their activities. The first 15 amino 
acids of the DrrB protein were fused to β-galactosidase as described under “Materials and 
Methods.” pDx109 and pDx178 are derived from pDx101 and pDx147, respectively. β-
Galactosidase activity of the fusion proteins encoded by pDx109 and pDx178 is shown on the 
right in Miller units/mg of total cell protein. 
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Fig.1.9: Effect of spacers on the expression of DrrA and DrrB proteins. I, Schematic 
representation of the clones pDx101 (drrAdrrB), pDx197 (drrA-17bp-drrB), pDx198 (drrA-
41bp-drrB) and pDx199 (drrA-68bp-drrB). The clones pDx197, pDx198 and pDx199 contain 
spacers of varying lengths between drrA and drrB. Two stop codons TAA and TAG have been 
inserted at the end of drrA in pDx197, pDx198 and pDx199. II, E. coli cells containing the 
indicated plasmids were induced with IPTG.  The cells were lysed by French press, followed 
by ultracentrifugation at 100,000 × g for 1hr to prepare membrane fractions.  25 µg of 
membrane protein was analyzed by SDS-PAGE on 12% gels, followed by Western Blot 
analysis using anti-DrrA (Panel A) or anti-DrrB (Panel B) antibodies. Lane 1, vector 
(pSU2718); lane 2, DrrA (pDx102);  lane 3, DrrB (pDx103); lane 4, DrrAB (pDx101); lane 5, 
DrrA+DrrB (pDx108 + pDx103) ; lane 6, DrrA-17bp-DrrB (pDx197) ; lane 7, DrrA-41bp-
DrrB (pDx198) ; lane 8, DrrA-68bp-DrrB (pDx199).   
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Mechanism(s) involved in controlling levels of DrrB 
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ABSTRACT 
 Biogenesis of membrane proteins is a poorly understood event. Several factors, both 
intrinsic and extrinsic, may aid in the assembly of protein complexes. The current study looks at 
the factors involved in the assembly of the DrrAB efflux pump that confers resistance to the 
commonly used anticancer drug, doxorubicin, in Streptomyces peucetius.  The DrrAB efflux 
pump is homologous to the ABC mammalian transporters; ABC1and P-glycoprotein (P-gp) and 
is expected to serve as a good model to understand assembly and function.  Previous study 
showed that the expression of DrrB is coupled to that of the upstream gene. A notable 
observation on coupling of drrB to an unrelated protein suggested that there was an unknown 
intrinsic mechanism within drrA that facilitates in optimizing the levels of DrrB. Rare codons 
and differential mRNA levels were ruled out as elements in regulation of DrrB levels.  In vitro 
protein translation studies brought forth the fact that translational arrest of DrrA may be a 
mechanism which, via translational coupling, could lower the levels of DrrB. A unique sequence, 
EEAAEEEKVA, in the C- terminal domain of DrrA was found to be involved in assembly of the 
two proteins DrrA and DrrB. Cysteine crosslinking analysis confirmed that the C terminus of 
DrrA is indeed involved in complex formation with the N terminus of DrrB. Based on the data 
presented in this study a model is proposed for the biogenesis of the DrrAB drug pump.   
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INTRODUCTION 
 The DrrAB efflux pump of Streptomyces peucetius imparts self-resistance to the drug 
doxorubicin. The DrrA protein has been identified as a 36kDa peripheral membrane protein and 
DrrB as a 30kDa integral membrane protein. Previous studies have shown that DrrB is dependent 
on DrrA for stability and DrrA is dependent on DrrB for function [4]. In the drrAB operon, the 
drrA and drrB genes have overlapping stop and start codons (ATGA) indicating translational 
coupling between the two genes. Recent studies have shown that drrB expression is 
translationally coupled to drrA. The intergenic region between drrA and drrB is predicted to 
form a stem loop structure (ΔG = - 19.0 kcal/mol) which would sequester the RBS and start 
codon of drrB[12]. In translationally coupled systems, ribosomes primed to the translation of 
upstream sequences are believed to dissipate the secondary structure and allow access to the SD 
and start codon[35]. This causes reinitiation and or de novo initiation of the translation of the 
downstream gene.  
 In the wild type drrAB system it was shown that translational coupling is indispensable 
for maintaining spatial proximity between the proteins and formation of a functional complex. 
An interesting observation was noted when drrB was translationally coupled to another gene(X), 
to give GeneXDrrB. The expression of DrrB from GeneXDrrB was increased by10 fold as 
compared to DrrADrrB. 
 A variety of mechanisms could account for this significant increase in the expression of 
DrrB when drrA was replaced by an unrelated gene.  These include presence of rare codons in 
DrrA, mRNA processing, or regulation at the level of translation.  Rare codons have been shown 
to be involved in reduced expression and translational errors such as frameshift or mistranslation 
in a number of systems[18]. The SsbB protein from Streptococcus pneumoniae is one such 
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example where the expression could be achieved in E.coli only after supplementing with rare 
codons on a plasmid[36]. RNA processing has also been suggested as a mechanism for achieving 
differential gene expression. This form of regulation by mRNA processing may also facilitate the 
biogenesis of certain systems such as the E.coli pilus determinants. In the pap operon of E.coli, 
the gene pair papBA is cotranscribed to form a minor fraction of mRNA, mRNA-BA. RNase E 
dependent cleavage occurs at the intercistronic region between papB and papA causing 
processing of the papB-mRNA and subsequent accumulation of the papA-mRNA. This leads to 
high level expression of PapA and aids in formation of pili [37].  
 Regulation at the level of translation can occur either due to RNA interactions or can be 
protein mediated. Protein-mediated translational regulation may be positive and cause activation 
of initiation, as in bacteriophage Mu where binding of Com protein to the Mom gene activates 
translation[38]. Likewise in some systems, protein-mediated negative regulation may cause 
repression of translation initiation. Some of the best studied examples include the MS2/R17 
replicase translation repression by the coat protein[39]. Negative feedback mechanisms can be 
accomplished in some systems by cooperative binding of protein to its mRNA (T4 gene 32), 
formation of pseudoknot structures (r-protein S15) or competitive binding between ribosome and 
proteins (r-protein S4 of the α operon)[19, 40]. 
 Control of translation via attenuation is another possibility. It is been well studied in the 
secMA operon belonging to the Sec system. In this system the secA gene is preceded by the 
secM gene and the two genes are translationally coupled[41]. It has been shown that translational 
attenuation in the last five codons of SecM, caused by stalling of ribosomes, opens the stem loop 
structure in the intergenic region between secM and secA, thereby allowing access to the Shine 
Dalgarno (SD) and leading to translation of secA[42, 43]. 
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 Several of these mechanisms were addressed in the current study to elucidate the 
mechanisms for regulation of expression of DrrB in the DrrAB system. It was found that even 
though rare codons are present in DrrA, they seem to play no role in expression.  It appears that 
at least one mechanism for regulation may be at the level of translation.  The most likely 
mechanism of control seems to lie in the upstream sequences of drrA which might act in co-
ordination with the last 30 base pairs of drrA in controlling the expression of DrrB. It is likely 
that mechanisms that lower levels of DrrB may involve attenuation of DrrA translation in the C 
terminus of DrrA, which through translational coupling may act to ensure reduced expression of 
DrrB.  A mechanism for involvement of the last ten amino acids of DrrA as well as translational 
coupling in assembly of the DrrAB complex is proposed. 
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MATERIALS AND METHODS 
Bacterial strains and plasmids.  The E. coli strains and plasmids used in this study are 
described in Table 2.1. 
Media and growth conditions.  The cells were grown in LB medium at 37°C.  M9 glucose 
medium was used where indicated.  Chloramphenicol was added to a final concentration of 20 
μg/ml and Ampicillin was added to a final concentration of 100 μg/ml.  Dox was added at the 
indicated concentrations to test for resistance. 
DNA manipulations.  The conditions for plasmid isolation, DNA endonuclease restriction 
analysis, ligation, and sequencing have been described elsewhere [27]. 
Creation of a drrB clone containing its own / indigenous RBS.  A putative RBS for the drrB 
gene is present within the C terminus of the drrA gene. To create a drrB clone containing its 
indigenous RBS, a two step mutagenesis was carried out to introduce wild type RBS upstream of 
drrB in the plasmid pDx103 (a clone containing drrB gene behind the RBS of arsA). The RBS 
in this clone was mutagenized to create the original RBS (AGGAG) of drrB by mutagenesis 
using Strategene QuikChange multisite-directed mutagenesis kit (La Jolla, CA). The strategy 
involved the use of complementary primers that incorporated the change at the required position. 
The nucleotide sequence of the primers used is indicated in Table 2.2. The amplified product 
bearing the mutation was then transformed into XL1 blue competent cells (provided by the 
manufacturer) and plated on medium containing chloramphenicol. Plasmid DNA was isolated 
from the colonies, and the desired mutation in the RBS of drrB gene was verified by sequencing 
of DNA. Sequencing was carried out using ABI 377 or 3100 sequencers (Applied Biosystems) in 
the Core Facilities in the Department of Biology at the Georgia State University.  The resulting 
mutant was named pDx152 in this study. Using the plasmid pDx152 as the template a three base 
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pair insertion (GGC) was introduced to obtain the wild type sequence (AGGAG) found 
preceding the drrB gene within the drrAB operon using primer sequence shown in Table 2.2. 
The resulting construct with the wild type RBS is called pDx153.  
Mutagenesis of the putative RBS of drrB. The following point mutation was introduced in 
drrAB using plasmid pDx101 as the template (Stratagene). The putative RBS of drrB present 
within drrA was mutated from AGGAG to AAGAA. The nucleotide sequence of the primers 
used is indicated in Table 2.2. The resulting mutant with the mutated RBS is called pDx148.  
Subcloning of DrrAB and GeneXDrrB into pET expression vectors.  The drrAB and 
geneXdrrB genes were sub-cloned from pDx101 and pDx150, respectively, into pET 11a vector 
using restriction enzymes NdeI and HindIII. The resulting plasmids were designated pDx139 and 
pDx146, respectively.   
Deletion of the last 10 amino acids of DrrA.  The last 30 base pairs of drrA were deleted from 
drrA by site-directed mutagenesis and from drrAB by sub-cloning.  A QuikChange multisite-
directed mutagenesis kit (La Jolla, CA) was used to delete the last 30 base pairs of drrA using 
the template pDx102.  The nucleotide sequence of the primers used is indicated in Table 2.2.  
The mutant thus obtained was called pDx183.  To delete this region from drrAB, pDx137 DNA 
was digested with XhoI (at 953th nucleotide in drrA) and FseI (at 84th nucleotide in drrB) to 
remove 132 bp from the intergenic region of drrAB.  A fragment was then created using 
mutually primed synthesis to convert the single-stranded oligonucleotides to double stranded 
heteroduplex form[29].  The oligonucleotides were designed such that the last 30 base pairs of 
drrA were deleted from the synthesized fragment. The following set of primers was used : 
Spacer 27 del: UP: 
5’GCCGATGACCGCTCGAGGGCATGACGACGTCCCCCGGCACCGTGGAATCCACGAC
50 
CCCTGTGAGCGGTCAGC 3’, Spacer 27 del: DN: 
5'CCGTCGCGCGGGCCGGCCGTTCACCCGCGGACAGCACCGTCCGCAGCTGACCGCT
CACAGGGGTCGTGGATT  3' 
The flanking regions contained XhoI and FseI restriction sites.  To carry out mutually primed 
synthesis, 100 μM each of the upstream and downstream primer were incubated at 23°C for 2 h.  
10 mM of dNTPs and 10 U of the Large Klenow fragment were added to the primers and 
incubation was carried out at 23°C for 1 h.  Additional 10 U of the Large Klenow fragment was 
added to the above reaction and the reaction was allowed to continue over night at 23°C in order 
to synthesize double stranded heteroduplex form of DNA.  The synthesized fragment was 
digested with XhoI and FseI and then ligated to the vector pDx137 that had been digested with 
XhoI and FseI.  The resulting clone has been designated pDx205.  The drrAB clone with 30 bp 
pair deletion was then sub cloned from pDx205 into pSU2718 using restriction enzymes NdeI 
and HindIII. The resulting plasmid was designated pDx200.   
Mutagenesis of rare codons in drrA.  The four rare codons (Thr:320, Thr:289, Pro:267 and 
Arg:268) of drrA were sequentially altered (Thr:320, Thr:289, Pro:267 and Arg:268) to 
commonly used E.coli codons [44] in the plasmid pDx139 by using a QuikChange multisite-
directed mutagenesis kit (La Jolla, CA).  The nucleotide sequence of the primers used is 
indicated in Table 2.2.  First, the codon at Thr:320 was changed.  This plasmid was named 
pDx171 in this study.  Using pDx171 as a template the next rare codon change was introduced at 
Thr: 289.  This strategy was used until a strain containing all four changes (pDx175) was 
obtained. 
Mutagenesis of the glutamic acid residues in drrA.  The five glutamic acid residues present in 
the last 10 amino acids of drrA were altered to glutamine, aspartic acid or glycine to produce 
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pDx186, pDx188 and pDx190.  The point mutations were carried out using pDx101 as a 
template by a QuikChange multisite-directed mutagenesis kit (La Jolla, CA).  The nucleotide 
sequence of the primers used is indicated in Table 2.2. The mutants were then sub-cloned from 
pDx186, pDx188 and pDx190 respectively, into pET 11a vector using restriction enzymes NdeI 
and HindIII. The resulting plasmids were designated pDx187, pDx189 and pDx191respectively.           
Mutagenesis of drrA to create single cysteine substitutions.  Single cysteine substitutions 
mutants were created at amino acid positions 319, 311, 302 and 287 in DrrA to produce pDx185,   
pDx206, pDx207 and pDx208, respectively. The point mutations were carried out using S23C as 
a template by a QuikChange multisite-directed mutagenesis kit (La Jolla, CA).  The nucleotide 
sequence of the primers used is indicated in Table 2.2.          
Translational Fusions of DrrB to β-Galactosidase.  A translational fusion of the first 15 amino 
acids of DrrB to the 8th amino acid of β-galactosidase was created.  Using the appropriate 
templates, the region containing the lac promoter and upto the 45th nucleotide of the drrB gene 
was polymerase chain reaction-amplified.  The primers had the following nucleotide sequence, 
and each primer contained a HindIII restriction site:  
UHAB 5’GCCGCCAAGCTTCCTCTCCCCGCGCGTTGG 3’; L15 5’ 
GCCGCCAAGCTTCGCTCACAGGGGTCGTGG 3’.  The amplified product was ligated to the 
translational fusion vector pMLB1069 that had been digested with HindIII [28].  Amplification 
and sub-cloning of the fragment from the following templates; pDx153, pDx171, pDx173 and 
pDx175 resulted in plasmids pDx154, pDx170, pDx172 and pDx174, respectively.  
The lacZ fusions, pDx166 (arsAΔ10aa drrB::lacZ) and pDx179 (arsARBSdrrB::lacZ), were 
created by site-directed mutagenesis by using specific primers (Table 2.2.) and pDx150 as the 
template.            
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Growth and Expression.  E.coli TG1 or HMS174 cells containing the indicated plasmids were 
grown to mid-log phase and induced with 0.1mM or 0.25 mM IPTG.  Growth was continued for 
an additional 3 h at 37°C.  The cells were spun down and lysed by a single passage through a 
French pressure cell at 20,000  p.s.i.  The cell lysates were centrifuged at 10,000 × g for 30 min 
to remove the unbroken cells.  The cell lysates were fractionated into cytosolic and membrane 
fractions by ultrcentrifugation at 100,000 × g for 1h.     The membrane fractions were solubilized 
in 4X Laemmli sample buffer by heating at 55°C for 10 min.  50 μg of membrane or cytosolic 
protein was analyzed by SDS-PAGE on 12% polyacrylamide gels, followed by Western blotting 
with either anti-DrrA, anti-DrrB, or anti-DrrA(C) antibodies.   
Measurement of β–Galactosidase activity.  The activity of the fusion proteins was determined 
by the methods published earlier [30].  Briefly, CC118 cells containing the fusion plasmid were 
grown to mid-log phase and induced with 0.25 mM IPTG for 3 h.  The cells were harvested and 
lysed by a single passage through a French pressure cell at 20,000 p.s.i.  The lysed cells were 
centrifuged at 10,000 × g for 30 min to remove unbroken cells.  100μg of lysate was added to a 
tube containing 1 ml of Z buffer (60 mM Na2HPO4, 40 mM NaH2PO4, 10 mM KCl, 1 mM 
MgSO4, and 50 mM β-mercaptoethanol).  The tubes were placed into a 37 °C water bath.  The 
reaction was started by adding 0.1 ml of o-nitrophenyl-β-D-galactopyranoside (4 mg/ml in Z 
buffer) to each tube.  Reaction was stopped by adding 0.5 ml of 1 M Na2CO3 once sufficient 
yellow color was developed.  The color was analyzed spectrophotometrically at 420 and 550 nm.  
The β-galactosidase activity units were calculated [30].   
Doxorubicin Resistance Assay.  Doxorubicin resistance assays were carried out on M9 plates 
supplemented with 0.25% casamino acids[27].  The plates were layered with 4 mL of top agar 
(0.8% agar in M9 medium) containing the desired concentration of doxorubicin.  Briefly, 4 mL 
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of top agar containing 0, 4, 6, 8, or 10μg/mL of doxorubicin (Sigma Chemicals) and 1 mM 
Thiamine-HCl was poured on top of M9 plates.  The plates were covered with foil to prevent 
exposure to light.  A doxorubicin sensitive strain of E. coli, N43, was transformed with the 
indicated plasmids.  Freshly transformed N43 strains were grown for 8 h in 3 mL of LB with the 
appropriate antibiotics.  Two microliters of the 8 h old N43 culture from above was streaked on 
the plates containing doxorubicin.  N43 containing the plasmid pSU2718 was used as a negative 
control.  The plates were then incubated at 37°C overnight, and growth was recorded after 24 h 
of incubation. 
In vitro coupled transcription and translation using bacterial lysates. Two μg of plasmid 
DNA was transcribed and translated in a 50µl reaction to using bacterial lysates (Ecopro, 
Novagen) according to the manufactures instructions.  The newly synthesized proteins were 
labeled with L-[35S]Methionine.  Rifamipicin was added to a final concentration of 1.5 μg to stop 
translation of other E.coli genes except the genes under the T7 promoter.  The reaction was 
carried out at 37°C for 1 hr.  The translated proteins were then analyzed on SDS-PAGE, 
following which they were fixed by 10% tricholoracetic acid.  The gel was then dried and 
followed with autoradiography.  
In vitro transcription-translation using rabbit lysates. 0.5 μg of plasmid DNA was transcribed 
to RNA using the STP3 transcription mix at 30°C for 15 mins. The transcribed product was then 
translated using rabbit lysates (STP3) commercially obtained from Novagen.  The newly 
synthesized proteins were labeled with L-[35S]Methionine.  The translation reaction was carried 
out at 30°C for 1 hr.  The translated proteins were then analyzed on SDS-PAGE, following 
which they were fixed by 10 % tricholoracetic acid.  The gel was then dried and followed with 
autoradiography.  
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RT-PCR. Total bacterial RNA was isolated from E.coli containing the plasmids pDx101, 
pDx102, pDx103, pDx150 or pDx108+pDx103 by SV Total RNA isolation system from 
Promega. Freshly isolated bacterial RNA was subjected to reverse transcription immediately. 
The cDNA synthesis was carried out by using AMV reverse transcriptase kit (Promega). The 
samples were then analyzed on 0.8% agarose gels and stained with ethidium bromide. The 
specific combinations of primers utilized for RT and PCR are shown in the Table 2.3. 
Chemical crosslinking. For homobifunctional crosslinking, a 100 μl reaction volume containing 
250 μg of cell membrane in 0.1M phosphate buffer pH 7.4 (0.1M of Na2HPO4 and 0.1M 
NaH2PO4) was treated with thiospecific reagents, Copper Phenanthroline (3mM CuSO4/9mM 1, 
10 Phenanthroline), DTME (Dithio-bis-maleimidoethane) (1mM), or MTS (3,6,9,12,15-
Pentaoxaheptadecane-1methanethiosulfonate)(1mM) for 30 minutes at room temperature. For 
heterobifunctional cross-linking, a 100μl reaction volume containing 250 μg of cell membrane in 
20 mM sodium phosphate pH 7.0 containing 150 mM NaCl was treated with GMBS (N-[γ-
maleimidobutyryloxy]sulfosuccinimide ester) (1mM) for 1 hr at room temperature in a light-
protected area. The reactions were terminated by the addition of 25 μl 4X non-reducing Laemmli 
sample buffer. The samples were mixed thoroughly and set aside for 5 min at room temperature. 
A 25 μl portion (50 μg of membrane protein) of the reaction mixture was then analyzed by 10% 
SDS-PAGE, followed by Western blot analysis using anti-DrrA, anti-DrrB or anti-DrrA(C) 
antibodies.  
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RESULTS 
Ribosome binding site of drrB is functional. The putative RBS (AGGAG) of drrB is located 
within drrA, 8 base pairs upstream of the DrrB start codon.   To test whether this RBS is utilized 
for the translation of drrB, a construct (pDx153) was generated, which contained drrB with the 
wild type RBS preceding it.   The membrane fractions were analyzed for the presence of DrrB by 
Western blotting using anti-DrrB serum.   No DrrB was detected in cells containing pDx153 in 
the absence of DrrA (Fig.2.1, lane 5).   This result was expected since DrrB requires DrrA for 
stability. To determine if DrrB is translated by utilizing this RBS, a lacZ fusion was created.  
This construct was called pDx154.   The amount of DrrB translated from this clone was similar 
to that from another construct containing E.coli RBS (pDx110) (Fig.2.2).   The above data 
indicate that the RBS of drrB in the wild type operon is as efficient as the E.coli RBS.   To 
further characterize the RBS a mutation of the RBS was created to obtain pDx148 (drrA-RBS*-
drrB).   The sequence of the mutated RBS was AAGAA.  The Western blot analysis using anti-
DrrB serum suggests that the amount of DrrB was significantly reduced in cells containing a 
mutation in the putative RBS of drrB (Fig.2.3, Panel B; lane 6).   These data suggest that in the 
wild type operon the RBS of drrB (embedded within drrA) must be functional.    
Effect of the last 30 bases of drrA on the expression of DrrB. The GeneXDrrB construct 
(pDx150) showed 10 fold higher expression of DrrB as compared to the DrrADrrB system. 
pDx150 contains 960 nucleotides of geneX, followed by the last 33 nucleotides of drrA, which 
are then coupled to the drrB gene, as seen in the wild type drrAdrrB operon. To understand the 
reason for the difference in the drrB gene expression in drrAB vs geneXdrrB, the last 27 
nucleotides from geneXdrrB were deleted and a lacZ fusion to the first 45 nucleotides was made 
(pDx166).The amount of DrrB translated from this construct (arsAΔ10aa drrB::lacZ) was 
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reduced to 30% as compared to drrAdrrB::lacZ (Table 2.4). The RBS was brought back into 
GeneXDrrB by creating the construct arsA-RBS-drrB::lacZ(pDx179). The levels of DrrB were 
restored to the same as those observed in GeneXDrrB, thus suggesting that the RBS was 
necessary for high expression of DrrB. Furthermore, these data (especially a comparison of 
drrAB::lacZ with geneXdrrB::lacZ) in Table 2.4 indicate that although DrrB is translated from 
this RBS the amounts of DrrB in the DrrAB system are reduced by the upstream sequences 
present in DrrA by an unknown mechanism, perhaps through some interaction with the region 
containing RBS in the C terminus of drrA. 
Comparison of mRNA levels in vivo.  A comparison of drrAB::lacZ and geneXdrrB::lacZ had 
shown that the level of translation of DrrB was 10 times higher from GeneXDrrB as compared to 
DrrAB.   To analyze whether differential mRNA levels play a role in down regulation of DrrB 
levels in DrrAB as compared to GeneXDrrB, mRNA levels were estimated by RT-PCR.   Total 
RNA was isolated from wild type E.coli cells expressing various plasmids.   Reverse 
transcription was carried out to selectively amplify cDNA corresponding to drrA, drrB, geneX, 
or the full length drrAB or geneXdrrB transcript.   The cDNA was then analyzed by agarose gel 
electrophoresis (Fig.2.4).   The data show that same amount of full length transcripts were seen 
in drrAB (Fig.2.4, lane 8) and geneXdrrB (Fig.2.4, lane 9).   Further, when individual genes 
were amplified by RT-PCR it was found that the levels of drrA in drrAB (Fig.2.4, lane 2) and 
geneX (Fig.2.4, lane 3) in geneXdrrB were same.   Likewise levels of drrB in drrAB (Fig.2.4, 
lane 6) vs. geneXdrrB (Fig.2.4, lane 7) were also similar.    
Role of rare codons in expression of DrrA and DrrB.  To estimate the frequency of rare 
codons in drrA as compared to geneX, the sequence of both the genes was analyzed by Codon 
Caltor.   The presence of single or consecutively placed rare codons could cause pausing or 
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stalling of ribosomes at the respective codon.   The possibility of translation arrest is higher at 
consecutively placed rare codons rather than solitary rare codons.    DrrA contains 46 single rare 
codons out of which 10 are consecutively placed as doublets or triplets (Table 2.5 and Table 2.6).   
GeneX contains 25 rare codons of which only two are placed as consecutive codons (Table 2.5 
and Table 2.6).    
 To determine if the high frequency of rare codons in DrrA is responsible for down 
regulating the translation of DrrA and subsequently that of DrrB, the cells were supplemented 
with tRNAs by using commercially available Novagen plasmids, pLysSRARE and 
pLysSRARE2.   The pLysSRARE plasmid codes for tRNA genes that decode all the rare codons, 
except for the arginine codons CGA (not found in DrrA) and CGG, and threonine codon ACG.   
The pLysSRARE2 plasmid decodes all rare codons except for the arginine codon CGA and 
threonine codon ACG.   β-galactosidase levels in geneXdrrB::lacZ (pDx151) and 
drrAdrrB::lacZ (pDx109) were determined on complementation of rare codons by either 
pLysSRARE or pLysSRARE2.   The amount of DrrB translated from both pDx151 and pDx109 
remained the same with or without complementation (Table 2.7), indicating that substitution of 
most rare codons by abundant codons did not increase translation of DrrA and DrrB.     
 Since all the rare codons, except threonines, were complemented by the plasmids 
pLysSRARE and pLysSRARE2, specific substitutions of some of these codons were made.   
Two threonines codons (ACG) at 289th and 320th amino acid and two consecutive rare codons 
(CCC, CGG) at 277th and 278th amino acid in DrrA were substituted by site-directed mutagenesis 
to those codons abundant in E.coli, yet encoding the same amino acid as the original codon.   
The substitutions involved a change from ACG to ACA at both 289th and 320th amino acids and 
from CCC CGG to CCA CGC at 277th and 278th amino acids.   Various strains resulting from 
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these mutations contained one, two or four codon substitutions.   The amount of DrrB translated 
after substitution of these codons is shown in Table 2.8.   The data showed that these changes, 
once again, did not enhance the DrrA and DrrB expression levels.   In fact, for unknown reasons, 
the strain containing substitution of four codons showed lower levels of translation as compared 
to the control. 
Possible translational mechanism(s) for controlling expression levels of DrrA and DrrB.   
In vitro translation.  
In vitro translation reactions were carried out using bacterial (Ecopro; Novagen) and rabbit 
reticulocyte lysates (STP3; Novagen) to investigate whether translational mechanisms regulate 
DrrA and DrrB protein expression.    
Translation in bacterial lysates: DrrA and DrrB proteins were transcribed and translated in vitro 
by using bacterial lysates (Ecopro from Novagen).   DrrA and DrrB expression was analyzed 
separately, in a trans combination, and in the wild type cis configuration. In this system, L-[35S] 
Methionine was used to label the proteins.   The proteins were separated by SDS-PAGE, 
followed by autoradiography.   Interestingly, in vitro analysis showed several species of DrrA 
(Fig. 2.5, lane 2, 4 and 5).The full length protein (35.6 kDa) of DrrA formed only a minor 
species.   The major translation product (sp.I) was slightly smaller and was of roughly 35 kDa 
molecular size.   Two other smaller species (sp.II ~ 31 kDa and sp.III ~ 29 kDa) were also 
detected. Interestingly, the full length protein was detected only when drrA was translated by 
itself (Fig.2.5, lane 2) or when translated in trans with drrB (Fig.2.5, lane 4).   No full length 
product was detected when drrAB genes were present in cis (Fig.2.5, lane 5).   Instead a higher 
species of about 66 kDa was seen in the cis configuration.   This species is likely to contain both 
DrrA and DrrB.   The presence of the 66 kDa species and concomitant absence of the full length 
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DrrA protein in cis configuration of drrA and drrB gene was intriguing and its possible 
significance is discussed later.   To determine if the smaller species of DrrA seen in this 
experiment are missing, sequences from the N terminus or C terminus of DrrA, a T7 tag (11 
amino acids long) was placed at the N terminus of DrrA in the DrrAB-containing clone.   On in 
vitro translation all three species (T7-sp.I, T7-sp.II and T7-sp.III) (Fig. 2.6, lane 2) migrated with 
slower mobility as compared to the three species of DrrAB without T7 tag (sp.I, sp.II and sp.III) 
(Fig. 2.6, lane 3).   These data indicate that the smaller DrrA species (sp.I, sp.II and sp.III) still 
contain the N terminus, but varying amounts of the C terminus of DrrA is missing in these 
products. 
 Another interesting observation was the difference in levels of DrrB in the presence and 
absence of DrrA.   The fewest amounts of DrrB were seen when the drrB gene was present alone 
(Fig.2.5, lane 4).   When drrB was translated in trans with drrA, the levels of DrrB were 
significantly reduced (Fig.2.5, lane 4).   Further reduction in the levels of DrrB is seen when 
DrrA and DrrB are translated in cis (Fig. 2.5, lane 5).    
 The presence of four species in DrrA might suggest some form of regulation affecting 
translation of DrrA.   As discussed earlier the ribosomal stalling at rare codons may cause 
premature termination of proteins.   Even though, in vivo studies showed that rare codons do not 
seem to play any role in reducing levels of DrrA, we wanted to determine if rare codon 
substitutions will have an effect on translation of proteins in vitro.   At the C terminus of DrrA, 
there are two threonines rare codons (ACG) at positions 289 and 320.   There is, in addition a 
consecutive pair of rare codons at position 277 and 278 in DrrA.   If the ribosomes stall at T320 
or T289 it could result in sp.I/34.5 kDa or sp.II/31.1 kDa peptides, respectively.   Similarly 
pausing of ribosomes at the consecutive rare codon doublet at P277, R278 could result in a sp.III/ 
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29.8 kDa species.   To investigate whether ribosomes stall at any of these 4 codons, constructs 
with codon substitutions (described earlier in this Section) were analyzed. In vitro translation 
analysis showed that the same three smaller species (sp.I, sp.II and sp.III) were still present in the 
translated proteins (Fig.2.7, lane 5, 6 and 7).   This indicates that the smaller species of DrrA 
(sp.I, sp.II and sp.III) are not the result of stalling at either of the following residues: T320, T289, 
P277, or R278. 
Translation in rabbit lysates: To confirm the results seen in the bacterial lysates (EcoPro), in 
vitro expression of DrrA and DrrB proteins was also carried out using rabbit reticulocyte lysates 
(STP3 from Novagen).  Data are shown in Fig. 2.8. There were many similarities to the results 
seen with Ecopro.   Full length DrrA was obtained only when drrA was translated by itself 
(Fig.2.8, lane 2) or when translated in trans with drrB and was present only in minor amounts 
(Fig.2.8, lane 4).   No full length product was detected when drrAB genes were present in cis 
(Fig.2.8, lane 5).   The major translated product (sp.I) still corresponded to a 35 kDa species, as 
was seen with Ecopro.   In the STP3 system, however, two smaller species (sp.II and sp.III) were 
not seen.   Further, the 66 kDa species was not observed in the STP3 system.   These differences 
may be due to much higher yield of DrrA translated product in Ecopro as compared to in STP3.    
In this experiment, GeneX was also used as a control.   GeneX contains 320 amino acids of ArsA 
followed by the last 10 residues from C terminus of DrrA. The total number of amino acids in 
GeneX is identical to DrrA.   The translation product of geneX was found to produce a single 
species corresponding to the full length product of 35.7 kDa (Fig.2.8, lane 6).   Both Ecopro and 
STP3 data suggest that the major translated species of DrrA; sp.I is smaller than the full length of 
DrrA, indicating that there may be some form of regulatory mechanism in DrrA that causes 
premature termination of translation.   Such a mechanism resulting in premature termination of 
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DrrA will simultaneously prevent expression of DrrB in the translationally coupled DrrAB 
system.  
In vivo analysis of translation products of GeneX and DrrA. To determine if the DrrA species 
translated in vivo is the full length DrrA or a smaller species as seen in vitro, DrrA and GeneX 
products were analyzed. DrrA and GeneX both contain 330 amino acids and both share a 
common 10 amino acid C terminal region. The expression of these proteins was probed by  
 Western blotting with anti-DrrA and anti- DrrA(C) (polyclonal antibody raised in rabbits to the 
last 10 amino acids of the C terminus of DrrA). Data in Fig. 2.9 show that full length GeneX can 
be detected using the anti-DrrA(C) since GeneX contains 30 amino acids of DrrA (Fig.2.9, Panel 
A; lane 6). DrrA could also be detected in membrane fractions of cells containing DrrA and DrrB 
(cis or trans) (Fig.2.9, Panel A; lanes 4 and 5), however DrrA was not seen in DrrA alone cells 
(Fig.2.9, Panel A; lane 2) with anti-DrrA(C). 
 To determine if the DrrA species seen in this experiment is the full length protein, E.coli 
cells were co-transformed with both geneXdrrB and drrA and the membrane fractions were 
analyzed by Western blotting with anti-DrrA(C). Two species were detected in the membrane 
fractions (Fig.2.9, Panel A; lane 7). The upper species (Fig.2.9, Panel A; lane 7) corresponds to 
that seen in GeneX (Fig.2.9, Panel A; lane 6) and the lower species to that detected in DrrA 
(Fig.2.9, Panel A; lane 4). This suggests that the species seen in DrrA is not the full length 
protein. The exact number of residues missing from the C terminus could not be determined. 
Role of the last 10 amino acids of the C terminus of DrrA.  Previous in vitro studies showed 
concomitant appearance of the 66 kDa species and disappearance of the full length DrrA protein 
on translation of lysates containing DrrAB in cis.   Since the 66 kDa species is produced only in 
the cis conformation and is likely to contain both DrrA (35.6kDa) and DrrB (30kDa).   GeneX in 
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GeneXDrrB contains 320 amino acids of ArsA and last 10 amino acids of DrrA and is 
translationally coupled to DrrB.   Interestingly, when geneXdrrB was translated in vitro, a 66 
kDa species was again observed (Fig.2.10, lane 9), as seen in drrAB (cis) (Fig.2.10, lane 5).   
This species was not seen in the trans combination of geneX and drrB (Fig.2.10, lane 8), again 
similar to the trans combination of drrA and drrB (Fig.2.10, lane 4).   The common region 
between DrrA and GeneX is the last 10 amino acids that come from the C terminus of DrrA.   
This region contains five glutamic acid residues.   It is possible that the negatively charged 
residues may be involved in interaction between DrrA and DrrB to form the 66 kDa species.   
However, if the 66 kDa species is a complex containing DrrA and DrrB, it is not clear how the 
proteins stay together after SDS-PAGE analysis.   An alternative explanation for this species can 
be that it is formed by codon skipping. Why such a situation is unlikely in the DrrAB system is 
discussed later.   Further analysis of this region was carried out as described below. 
Glutamic acid (E) substitutions.  To determine if the negatively charged glutamic acid (E) 
residues present in the C terminus of DrrA were involved in the formation of the 66 kDa species, 
substitutions of the glutamic acid residues were carried out to create strains containing three or 
four substitutions.   These include DrrA E(321, 322, 325)D, DrrA E(321, 322, 325)G, DrrA 
E(321, 322, 325, 326)Q.   The expression of DrrA and DrrB proteins in these strains was 
determined.   Western blot analysis carried using anti-DrrA and anti-DrrB antibodies suggest that 
the expression of DrrA (Fig.2.11, Panel A; lane 3, 4 and 5) and DrrB (Fig.2.11, Panel B; lane 3, 
4 and 5) after substitution remained the same as in the wild type (Fig.2.11, Panel A and B; lane 
2).   The effect of the substitutions on doxorubicin resistance was also tested.   Data in Table 2.9 
show that glutamic acid substitutions result in sensitivity to doxorubicin, indicating that the 
glutamic acid residues are important for function.   Together, the Western blot analysis and 
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doxorubicin resistance assays suggest that these glutamic acid residues are not involved in DrrA 
and DrrB interaction required for stability of proteins, but they do play a role in functional 
interaction.  
Deletion of the last 10 amino acids of the C terminus of DrrA.  The last 10 amino acids of the 
C terminus of DrrA were deleted from DrrA, DrrAB and GeneXDrrB, as described in Material 
and Methods.   The membrane fractions were analyzed by Western blotting with anti-DrrA, anti-
DrrB and anti- DrrA(C) serum generated to the last 10 amino acids of the C terminus of DrrA.   
The truncated DrrA protein migrated lower at 34.5 kDa (Fig.2.12, Panel A; lane 6, 7 and 8) and 
was found to be more stable by itself (Fig.2.12, Panel A; lane 6) as compared to DrrA (Fig.2.12, 
Panel A; lane 2).   As expected DrrAΔ10aa could not be detected by the anti-DrrA(C) anti- sera 
(Fig. 2.12, Panel C; lane 6).   However, DrrAΔ10aa was able to stabilize DrrB both in cis 
(Fig.2.12, Panel B; lane 8) and trans (Fig.2.12, Panel C; lane 7) configurations, again suggesting 
that the C terminus of DrrA is not required for stabilization of DrrB by DrrA.  
 To determine if the DrrAΔ10aa DrrB protein conferred resistance to doxorubicin, plasmid 
pDx200 was transformed into N43.   Doxorubicin resistance assays showed that cells containing 
pDx200 expressing the DrrAΔ10aa DrrB proteins were doxorubicin sensitive (Table 2.9).   This 
suggests that although the last 10 amino acids of DrrA are not required for stabilization of DrrB, 
they seem to play an important role in functional complex formation.    
In vitro analysis of glutamic acid (E) mutants.  In vitro coupled transcription and translation of 
“E” mutants was carried out using bacterial lysates (Ecopro). The “E” mutants showed the same 
pattern of expression for DrrA as seen for the wild type DrrAB system (Fig.2.13, lane 6, 7 and 8) 
including the 66 kDa species (Fig.2.13, lane 5) as seen in the wild type DrrAB cis system.   The 
E (321, 322, 325, 326) Q mutant showed the least amount of 66 kDa species.   These data 
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suggest that the negatively charged “E” residues may play some role in the formation of the 66 
kDa species.   Functional studies shown in Table 2.9 indicate that glutamic acid residues in the C 
terminus of DrrA are required for function of the complex. 
In vitro analysis of clones containing a deletion of the last 30bp (DrrAΔ10aa and 
DrrAΔ10aaDrrB).  A deletion of the last 10 amino acids is expected to result in a DrrA 
polypeptide of 34.5 kDa in size.  In vitro translation of DrrAΔ10aaDrrB and DrrAΔ10aa was 
carried out using bacterial lysates (Ecopro).  Both the DrrAΔ10aa (Fig.2.14, lane 4) and 
DrrAΔ10aaDrrB (Fig.2.14, lane 3) showed a product of the same size (sp.IV and sp.V), which is 
slightly smaller than the major (sp.I) in vitro translated product of DrrAB (~ 35 kDa) (Fig.2.14, 
lane 2).  These data indicate that the major species (sp.I) (Fig.2.14, lane 2 and 5) is missing less 
than 10 amino acids from the C terminus of DrrA. 
In vitro studies of uncoupled mutants.  To determine if coupling plays a role in the formation 
of the 66 kDa species, DrrAB clones containing long spacers between drrA and drrB gene 
(described earlier in Chapter 1, Material and Methods) were analyzed.  Briefly, the overlapping 
start and stop codons were removed in these constructs.  Two stops codons (UAA, UAG) were 
placed at the end of drrA followed by 17, 41 or 68 bp long spacers.   In vitro translation showed 
that full length DrrA protein was absent in constructs containing 17bp and 41bp long spacers 
(Fig.2.15, lane 6 and 7).   As seen in the wild type system, these two constructs also showed 
concomitant formation of the 66 kDa species.   The construct with 68bp spacer showed different 
results.   Not only was a small amount of full length DrrA seen, but also the 66 kDa species was 
absent, thereby changing the system to the one resembling the trans conformation.  Since the 66 
kDa species was formed in constructs with spacers up to a distance of 41 bp but is absent in the 
construct with 68 bp spacer it indicates that at a distance between 41bp and 68bp the two genes 
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become completely uncoupled.   Functional studies previously discussed (Table 2.9) showed that 
introduction of any of these three spacers confers doxorubicin sensitivity.   These data suggest 
that translational coupling, including the overlapping start and stop codon is required for 
function.  It is also likely that the 66 kDa species may be important for function, even though it is 
clear, from the data shown in Fig. 2.10 that this species can form even if only the last 10 amino 
acids (30bp) of DrrA are present, as seen in GeneXDrrB.   
Is the C terminus of DrrA involved in complex formation with DrrB? To determine if the 
last 10 amino acids of the C terminus of DrrA were involved in complex formation with DrrB, 
disulphide crosslinking using hetero and homo bifunctional crosslinkers was carried out.   DrrB 
contains one cysteine residue at position 260.   Using a cysteine-less variant of DrrB, several 
cysteine substitutions in DrrB were created previously [10].   By using a cysteine to amine 
crosslinker, GMBS, it was shown that the N terminus of DrrB is involved in interactions with 
DrrA.   S23C, a substitution in the N-terminal cytoplasmic tail of DrrB showed the best 
crosslinking with DrrA [10].   In this study, DrrADrrB(S23C) was used as a template to 
introduce cysteines at residues 319, 311, 302 or 287 in DrrA, which precede the last 10 amino 
acids of DrrA.   To determine if the N terminus of DrrB (S23C substituted) interacts with the C 
terminus of DrrA disulphilde crosslinking was carried out.   Three homo bi-functional 
crosslinkers of different arm lengths, including, CuPhe (0 Ǻ), DTME (13.3 Ǻ) and MTS (24.0 
Ǻ), were used.   A 66 kDa species corresponding to a complex of DrrA and DrrB is seen when 
membranes containing DrrADrrB(S23C) are crosslinked using GMBS; this has been observed 
before [10] and hence served as a control in this experiment (Fig.2.16, lane 2). Interestingly, 
when membranes containing DrrA(S319C)DrrB(S23C) were treated with the homobifunctional 
crosslinkers mentioned above, a DrrA-DrrB disulphide crosslinked species of 66 kDa was seen.   
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Most efficient crosslinking was seen with DTME (Fig.2.16, lane 4) and least with the longest 
arm length crosslinker MTS (Fig.2.16, lane 6).    
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DISCUSSION 
 The current study investigated the possible mechanism(s) that cause reduced expression 
of DrrB in the wild type DrrAB system.  A number of interesting clues towards the assembly of 
the complex were found.   
 Translational coupling was found to be operational in DrrAB.  The RBS of drrB 
embedded within the stem loop was found to be functional.  A mutation in this RBS significantly 
reduced the expression of DrrB.  Deletion of the RBS from GeneXDrrB (arsAΔ10aa drrB) 
significantly reduced the expression of DrrB.  The expression was restored to the original level 
on bringing back the RBS (arsA-RBS-drrB).  By using RNA secondary structure prediction 
software, we found that that a secondary structure (ΔG = -19.0 kcal/mol) is possible in the 
intergenic region between drrA and drrB[31]. The RBS and the start codon of DrrB are 
predicted to be occluded in this secondary structure. It is believed that in translationally coupled 
systems, ribosomes primed to the upstream ORF open up the stem loop structure, thus allowing 
translation of the downstream gene. Therefore it can be concluded that although the RBS of drrB 
may be occluded, it is functional when available. 
 To determine if regulation in the DrrAB system occurred at the level of transcription, 
transcripts of drrA and drrB were quantitated by RT-PCR.  RT-PCR showed that the amounts of 
the mRNA transcripts were identical, therefore differential gene expression or mRNA stability 
was ruled out as a mechanism of regulation.  Further, the drrAB system originates from 
Streptomyces peucetius, therefore its expression may be affected in the heterologous host E.coli.  
Although there are forty six rare codons in drrA as compared to twenty five in geneX, 
complementation with plasmids decoding rare codons showed no improvement of expression in 
DrrAB[44]. 
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 In vitro transcription translation system(s) provided important insights.  DrrA protein  
showed four species (Full length, Major/sp.I, sp.II and sp.III) when translated by itself and three 
species (Major/sp.I, sp.II and sp.III) when translated in cis with DrrB.  Out of the four species the 
largest was identified as the full length DrrA using GeneX as the control.  The second species 
(Major/sp.I) was the major translated product.  The presence of these species in a cell/protease- 
free system raised the following questions: 1. Are the species missing the N- or C- terminal 
sequences? 2.  Are these species formed due to stalling of ribosomes at rare codons?  
3.  Does DrrA act as an autoregulator? 4. Is translational arrest a form of regulatory control in 
DrrA? 5.  Is there a riboswitch control in DrrA that regulates levels of DrrB? 
 An attempt to answer some of the above questions was made.  On tagging DrrA in the 
DrrAB system with an 11 amino acid T7 tag at the N terminus, all three species of DrrA moved 
with slower mobility on the SDS-polyacrylamide gel.  These data suggested that the N terminus 
of DrrA was intact and that the species I, II and III are missing some sequence from the C 
terminus.  The clue for the missing residues of the C terminus seemed to lie within the last ten 
amino acids of DrrA.  Therefore a construct with deletion of the last ten amino acids of DrrA 
from DrrAB was made and the translated product, sp.IV, was observed to run at the same size of 
sp.II.  This indicates that the major species or sp.I of DrrA is missing less than ten amino acids 
from the C terminus.  In vivo data supported this finding and revealed that the major species seen 
in vivo was not the full length but probably the next species-sp.II/ major species.   
 Our next question was to find out whether ribosomal stalling occurred at this region due 
to presence of rare codons? Since the commercial plasmids did not complement the threonine 
codons in drrA four rare codon substitutions were made.  The 320th codon in DrrA is threonine, 
which could not be complemented.  A mutation was made in this codon to an abundantly used 
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threonine codon in E.coli.  This substitution did not have an effect on pattern of in vitro 
translation of DrrA and was ruled out as a cause of stalling.  Since DrrA produced four species it 
was highly likely that there is an autoregulatory mechanism in DrrA, possibly through 
translational arrest.  This arrest may be due to either autogenous signal such as the RNA 
sequences of drrA which may form a pseudoknot and repress translation or the DrrA protein 
repressing its own mRNA.  The trigger may be the levels of DrrAB complex in the membrane. 
Using the RibEx software, drrA and drrB sequence was analyzed for consensus sequences of 
possible regulatory elements such as riboswitches, transcriptional, or translational 
attenuators[45]. DrrA was found not to contain any consensus sequences for known 
riboswtiches; however a translational attenuator was identified in DrrA at the 214th amino acid 
by the RibEx software[45]. If a translational arrest occurred at the 214th amino acid in DrrA a 
peptide of 23 kDa would result. On in vivo analysis of DrrA, a 23 kDa peptide was indeed 
detected; however it has not been further analyzed in the current study. The possibility of 
translational arrest within DrrA at two possible sites; the predicted attenuator at 214th amino acid 
and in the C terminus of DrrA cannot be ruled out. Considering all the available leads, the most 
likely possibility is that some upstream sequences interact with the last 30 base pairs of drrA 
(which happen to contain the RBS for drrB) and cause translational attenuation at the last ten 
amino acids of DrrA and regulate the levels of DrrB through translational coupling. Translational 
regulation by attenuation or translational arrest has best characterized in the secMA operon 
belonging to the Sec system. In this system the gene pair secMA is translationally coupled[41]. 
Ribosomal stalling at the last five codons of SecM causes an increase in local concentration of 
ribosomes on the mRNA which opens the stem loop structure in the intergenic region between 
secM and secA, thereby permitting the ribosomes to contact the SD and initiate translation of 
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secA [42, 43]. Furthermore, it has been suggested that the secA conformation depends on 
translational coupling to the upstream gene secM, as seen in the DrrAB system (Chapter 1). 
 Another interesting phenomenon observed in this study was the complete absence of full 
length DrrA and concomitant presence of a 66 kDa species in the DrrAB cis system (wild type) 
on in vitro translation. Since the same species was also produced in the GeneXDrrAB system 
(GeneX contains the last 10 amino acids from the C terminus of DrrA), it is likely that this 
species contains a monomer of DrrA (36 kDa) and a monomer of DrrB (30 kDa), or GeneX (36 
kDa) and DrrB (30 kDa). It raised the possibility that the C terminus of DrrA may contain an 
interaction domain for DrrB. The formation of this species in the DrrAB system suggested that 
the full length DrrA was probably involved in the formation of this 66 kDa species and was 
therefore itself missing.  The C terminus of DrrA contains a rather unique sequence in which five 
out of ten residues are glutamic acid residues, EEAAEEEKVA.  Deletion of the last ten amino 
acids from DrrAB resulted in an inability to form this 66 kDa species, suggesting that the 66 kDa 
species contained the entire DrrA including the last ten amino acids.  In vivo functional studies 
showed that DrrAB missing the last 10 amino acids of DrrA conferred doxorubicin sensitivity 
although the genes were still translationally coupled.   Furthermore, it was found on substitution 
of the glutamic acid residues that doxorubicin resistance was not conferred even though the 
substitution was from glutamic acid to aspartic acid, both of which are negatively charged.  In 
vitro translational analysis showed that the 66 kDa species was still formed when glutamic acid 
residues were substituted with aspartic acid or glycine, but was most affected in the glutamine 
substitution.   The only definite conclusion that can be drawn was that although the negatively 
charged glutamic acid (E) residues are important for functional DrrAB complex formation, their 
role in the 66 kDa species formation is ambiguous.   
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The possibility of reprogramming of translation in the intergenic region of DrrA and 
DrrB in the formation of the 66 kDa species was considered. Reprogramming of translation can 
take place by either frameshifting or bypassing[46].  Frameshifting has been observed to occur 
due to slippage to +1 or -1 frame in some systems, which could result either in formation of a 
shorter protein or a fusion protein. In the E.coli DNA polymerase, the τ subunit (71 kDa) is the 
complete product of the gene dnaX, whereas the γ subunit (47 kDa) is a protein formed due to a 
translational frameshift in the N terminus of dnaX leading to a -1 frame UGA codon[47]. The 
frameshift requires the presence of a slippery heptamer sequence (A-AAA-AAG) followed by a 
stem loop at the C terminus [48, 49]. In dnaX, a shifting in this site encounters a UGA stop 
codon two codons downstream.  There is no evidence of any heptameric motif that could cause 
frameshifting in the C terminus of DrrA. Translational by-passing or hopping involves shifts that 
occur in large increments (which may or may not include a stop codon) and have been found to 
display certain basic features. The presence of identical or synonymous codons at the flanking 
regions of the by-passed nucleotides where the tRNA takes off and lands, stem loop structures, 
and a mix of charged polar and hydrophobic amino acids are some of the basic requirements [46, 
50].  In the phage T4 gene 60 the tRNA can by-pass as many as 50 nucleotides that include a 
stop codon and reinitiate at a start codon [50, 51]. In the DrrAB system two identical alanine 
codons, GCA, are present 16 bases apart and were considered as candidate take off and landing 
sites. The introduction of a 17 base pair or a 41 base pair spacer between drrA and drrB 
produced a species similar to the 66 kDa.  The construct with a 68 base pair spacer however did 
not show the higher species but its translational pattern was exactly similar to DrrA by itself.  
These spacers introduced between drrA and drrB contained two stop codons following the drrA 
sequence. All three spacers contained identical or synonymous alanine codons at a distance of 
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either 17 (Spacer 1) or 24 (Spacer 2 and Spacer 3) bases apart. Yet only two of the three 
constructs (Spacer 1 and Spacer 2) produced a species similar to the 66 kDa species seen in 
DrrAB. This data suggest that the 66 kDa species seen on in vitro translation may not be a 
product of translational by-passing. It is however possible that the two genes are still 
translationally coupled and therefore form the 66 kDa in the 17 and 41 bp spacer constructs and 
that  complete uncoupling occurs only in the construct with 68 bp spacer. Although introduction 
of all of the three spacers confers doxorubicin sensitivity in vivo, the role of the 66 kDa in 
function is unclear.  It is clear that this species can form even if only the last ten amino acids 
(30bp) of DrrA are present, as seen in GeneXDrrB.      
Finally, to determine if the C terminus of DrrA interacts with DrrB and if indeed the 66 
kDa could result from such an interaction, disulphide crosslinking was carried out. Of the four 
cysteine substitutions made, DrrA(S319C) just preceding the last 10 amino acids showed good 
disulphide crosslinking with the N terminus of DrrB.  The cysteine substitution DrrA(T311C) 
showed lesser amount of crosslinked product with the N terminus of DrrB as compared to 
DrrA(S319C). The other two cysteines, DrrA(S302C) and DrrA(S287C), did not crosslink with 
the N terminus of DrrB. From the crosslinking studies it can be speculated that this ten amino 
acid sequence is unique and may be a key to formation of complex of the DrrA and DrrB 
proteins. 
 In summation a model is proposed based on the above studies.  This model suggests that 
translational arrest in the C terminus of DrrA plays a role in controlling the levels of DrrB via 
translational coupling. The regulation also involves upstream sequences to cause premature 
translational termination in DrrA.  The translational arrest leads to reduced expression of DrrB 
and plays a role in controlling it to the optimal amounts.  During formation of complex of DrrA 
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and DrrB, the C terminus domain of DrrA binds to the N terminus of DrrB only when the genes 
are in cis.  This unique C terminal domain interacts with DrrB and the interaction may further 
lead to the targeting of the complex into the membrane to achieve a successful functional 
assembly. 
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Table 2.1: Bacterial strains and plasmids 
Strains and plasmids 
Strains or 
plasmids 
Genotype or description Reference or 
source 
Strains   
CC118 F-araD139_(ara-leu)7697_lacX74_phoAD20galK16 thi rpsE rpoB argE(Am) 
recA1 
[33] 
TG1 K-12 D(lac-pro) supE thi hsdD5/F9 tra36 proA1B1 lacIq lacZDM15 [27] 
N43 ara-14 Dlac-85 acrA1 supE44? galK2 rpsL197 malA1 (lr) xyl-5 mtl-1 [34] 
XL-1Blue recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F´ proAB lacIqZΔM15 
Tn10 (Tetr)] 
[27] 
HMS174 K-12 F- recA1 hsdR(rK12- mK12+) (Rif R) [27] 
Plasmids   
pDx101 PlacdrrAB in pSU2718 [4] 
pDx102 PlacdrrA in pSU2718 [4] 
pDx103 PlacdrrB in pSU2718 [4] 
pDx108 PlacdrrA in pUC18 [5] 
pDx109 PlacdrrA-drrBfirst45nts-lacZ fusion [5] 
pDx110 PlacdrrBfirst45nts-lacZ fusion [5] 
pDX113 PT7drrB in pET11a This lab 
pDx114 PT7drrAB in pET11a (with T7-tag) This lab 
pDX124 PT7drrA in pET11a This lab 
pDx137 PT7drrA-XhoI site introduced before drrA stop-drrB in pET11a This study 
pDx139 PT7drrAB in pET11a (without T7-tag) This lab 
pDx145 PT7arsAfirst960nts-drrAlast33nts in pET11a This study 
pDx146 PT7arsAfirst960nts-drrAlast33nts-drrB in pET11a This study 
pDx148 PlacdrrA-drrB-RBS mutated-drrB in pSU2718 This study 
pDx150 PlacarsAfirst960nts-drrAlast33nts-drrB in pSU2718 This study 
pDx151 PlacarsAfirst960nts-drrAlast33nts-drrBfirst45nts-lacZ fusion This study 
pDx153 PlacdrrB in pSU2718 (wild type drrB RBS from drrA) This study 
pDx154 PlacdrrBfirst45nts-lacZ fusion (wild type drrB RBS from drrA) This study 
pDx166 PlacarsAfirst960nts-drrAlast3nts-drrBfirst45nts-LacZ in pMLB1069 This study 
pDx170 PlacdrrA320T-drrBfirst45nts –LacZ in pMLB1069 This study 
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pDx171 PT7drrA320T-drrB in pET11a This study 
pDx172 PlacdrrA320T+289T-drrBfirst45nts –LacZ in pMLB1069 This study 
pDx173 PT7drrA320T+289T -drrB in pET11a This study 
pDx174 PlacdrrA320T+289T+277+278-drrBfirst45nts –LacZ in pMLB1069 This study 
pDx175 PT7drrA320T+289T+277+278-drrB in pET11a This study 
pDx179 PlacarsAfirst960nts no drrA-RBS of drrB-drrBfirst45nts-lacZ fusion in pMLB1069 This study 
pDx182 PT7DrrAΔlast10amino acids in pET11a This study 
pDx183 PlacDrrAΔlast10amino acids in pSU2718 This study 
pDx185 PlacDrrAS319CDrrBS23C  This study 
pDx186 PlacDrrAE320,319,316GDrrB in pSU2718 This study 
pDx187 PT7DrrAE320,319,316GDrrB in pET11a This study 
pDx188 PlacDrrAE320,319,316DDrrB in pSU2718 This study 
pDx189 PT7DrrAE320,319,316DDrrB in pET11a This study 
pDx190 PlacDrrAE320,319,316,315QDrrB in pSU2718 This study 
pDx191 PT7DrrAE320,319,316,315QDrrB in pET11a This study 
pDx200 PlacdrrA-XhoI site introduced before drrA stop-lastΔ 10aaof drrA-drrB in 
pSU2718 
This study 
pDx201 PT7drrA-XhoI site introduced before drrA stop-18bp spacer-drrB in pET11a This study 
pDx202 PT7drrA-XhoI site introduced before drrA stop-48bp spacer-drrB in pET11a This study 
pDx203 PlacdrrB in pUC18 This study 
pDx204 PT7drrA-XhoI site introduced before drrA stop-72bp spacer-drrB in pET11a This study 
pDx205 PT7drrA-XhoI site introduced before drrA stop-Δlast 10aa of drrA-drrB in 
pET11a 
This study 
pDx206 PlacDrrAT311CDrrB S23C  This study 
pDx207 PlacDrrAS302CDrrBS23C  This study 
pDx208 PlacDrrAS287CDrrBS23C  This study 
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Table 2.2: Sequence of primers used for creating site-directed mutants. 
 Plasmid Primer name Primer sequence 
C-RBS-UP 5’ GAAGAAGCGGCGGAAGAAAAGGTGGCATGA3’ 1. 
 
pDx148 
C-RBS-DN 5’ TCATGCCACCTTTTCTTCCGCCGCTTCTTC3’ 
110-1-UP 5’ TTAAGTATATCAGGAGAAGGTATGACGACGTCCCCC 3’ 2. pDx152 
110-1-DN 5’GGGGGACGTCGTCATACCTTCTTCTGATATACTTAA 3’ 
110-2-UP 5’AGTATATCAGGAGAAGGTGGCATGACGACGTCCCCC3’ 3. pDx153 
110-2-DN 5’GGGGGACGTCGTCATGCCACCTTCTCCTGATATACT3’ 
150-27bpdel-UP 5'CTTTCTGCGTTGCTCGAGGCATGACGACGTCCCCCG3' 4. pDx166 
150-27bpdel-DN 5'CGGGGGACGTCGTCATGCCTCGAGCAACGCAGAAAG 3'  
drrA-320-Thr-UP 5'CGATGACCGGTCCAC AGAAGAAGCGGCGG 3' 5. pDx171 
drrA-320-Thr-DN 5'CCGCCGCTTCTTCTGTGGACCGGTCATCG 3' 
drrA-289-Thr-UP 5'GCCGAGCTGTCGCGCACACACTTGGAGGTACGC3' 6. pDx173 
drrA-289-Thr-DN 5'GCGTACCTCCAAGTGTGTGCGCGACAGCTCGGC3' 
drrA-267,268-
Pro,Arg-UP 
5'GCGCGGATCGACGACCCACGCCAGGGCATGCGGGCC 3' 7. pDx175 
drrA-267,268-
Pro,Arg-DN 
5'GGCCCGCATGCCCTGGCGTGGGTCGTCGATCCGCGC 3' 
XXB-UP 5’GCGTTGCTCGAGGATATTGCCCGTAATGAGGAGGGCCTGGCA 
TGACGACGT3' 
8. pDx179 
XXB-DN 5' ACGTCGTCATGCCAGGCCCTCCTCATTACGGGCAATATCCTC 
GAGCAACGC3' 
11a-drrA-del320-
330-UP 
5'GATGACCGGTCCACGTGACGAAAGCTGATC3' 9. pDx182 
11a-drrA-del320-
330-DN 
5'GATCAGCTTTCGTCACGTGGACCGGTCATC3' 
10. pDx183 102-drrA-del320- 5'GATGACCGGTCCACGTGACGAAGCTTGGCA3' 
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330-UP 
102-drrA-del320-
330-DN 
5'TGCCAAGCTTCGTCACGTGGACCGGTCATC3' 
DrrA 319 S to C–
UP 
5'GCCGATGACCGGTGCACGGAAGAAGCG 3' 11. pDx185 
DrrA 319 S to C-
DN 
5' CGCTTCTTCCGTGCACCGGTCATCGGC3' 
drrA E to G-UP 5'TCCACGGGAGGAGCGGCGGGAGAGGAG 3' 12. pDx186 
drrA E to G-DN 5'CTCCTCTCCCGCCGCTCCTCCCGTGGA 3' 
drrA E to D-UP 5' TCCACGGATGATGCGGCGGATGAGGAG 3' 13. pDx188 
drrA E to D-DN 5'CTCCTCATCCGCCGCATCATCCGTGGA 3' 
drrA E to Q-UP 5'TCCACGCAACAAGCGGCGCAACAGGAGAAG 3' 14. pDx190 
drrA E to Q-DN 5'CTTCTCCTGTTGCGCCGCTTGTTGCGTGGA 3' 
Spacer 27 del: UP 5’GCCGATGACCGCTCGAGGGCATGACGACGTCCCCCG 
GCACCGTGGAATCCACGACCCCTGTGAGCGGTCAGC 3’ 
15. pDx200 
Spacer 27 del: DN 5'CCGTCGCGCGGGCCGGCCGTTCACCCGCGGACAGCA 
CCGTCCGCAGCTGACCGCTCACAGGGGTCGTGGATT  3' 
T311C-UP 5'TTCCTGGCGCTGTGCGGCCACCCGGCC3' 16. pDx206 
T311C-DN 5'GGCCGGGTGGCCGCACAGCGCCAGGAA3' 
S302C-UP 5'CTCGGCCAGTCCTGTCTCGACGAGGTC3' 17. pDx207 
S302C-DN 5'GACCTCGTCGAGACAGGACTGGCCGAG3' 
S287C-UP 5'CTGGCCGAGCTGTGCCGCACGCACTTG 3' 18. pDx208 
S287C-DN 5'CAAGTGCGTGCGGCACAGCTCGGCCAG3' 
 
 
 
78 
Table 2.3: Primers used for RT-PCR. The table includes set of upstream and downstream 
primers, the RNA templates and fragment amplified for RT-PCR analysis. 
Lanes Primer-UP Primer-
DN 
RNA template Fragment 
amplified 
1. AI AII A+B-108+103 drrA 
2. 1704 A II AB-101 drrA 
3. 1704 A II XB-150 geneX 
4. BI B II B-103 drrB 
5. B I B II A+B-108+103 drrB 
6. B I B II AB-101 drrB 
7. B I B II XB-150 drrB 
8. 1704 B II AB-101 drrAB 
9. 1704 B II XB-150 geneXdrrB 
 
Table 2.4: Effect of deletion of the last 10 amino acids from GeneXDrrB. I, Schematic 
representation of the fusion proteins; pDx109 (drrAdrrB::lacZ), pDx151 (geneXdrrB::lacZ), 
pDx166 (arsAΔ10aa drrB::lacZ) and pDx179 (arsA-RBS-drrB::lacZ). II, β-Galactosidase activity 
of the fusion proteins encoded by indicated plasmids is shown on the right as percentage of 
Miller units/mg of total cell protein. 
     I       II 
  
 
 
 
 Construct Fusion protein % 
1. pDx109 drrAdrrB::lacZ 100 
2. pDx151 geneXdrrB::lacZ 900 
3. pDx166 arsAΔ10aa drrB::lacZ 30 
4. pDx179 arsA-RBS-drrB::lacZ 1100 
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Table 2.5: Distribution of rare codons in drrA and geneX[44]. The table depicts the difference 
between the numbers of rare codons found in drrA v/s geneX calculated by the internet based 
program Rare Codon Caltor. 
Amino Acid Rare codon Frequency of 
Occurrence in drrA 
Frequency of 
Occurrence in 
geneX 
CGA 0 1 
CGG 17 5 
AGG 3 1 
 
Arginine 
AGA 0 1 
GGA 1 3 Glycine 
GGG 5 2 
Isoleucine AUA 0 2 
Leucine CUA 0 0 
Proline CCC 4 4 
Threonine ACG 16 6 
Total  46 25 
 
 
Table 2.6: Distribution of repeated and/or consecutive rare codons in drrA and geneX[44]. 
The table depicts the difference between the numbers of consecutive rare codons found in drrA 
v/s geneX calculated by the internet based program Rare Codon Caltor. 
 
 
 
Repeated and/or consecutive rare codons  
GGG ACG AGG 1 
CGG CGG CGG 1 
ACG ACG 2 
 
 
drrA 
CCC CGG 1 
geneX ACG CGG 1 
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Table 2.7: Translational levels with or without complementation by pLysSRARE and 
pLysSRARE2. β-Galactosidase activity of the fusion proteins encoded by indicated plasmids 
when complemented with either pLysSRARE or pLysSRARE2 is shown on the right as 
percentage of Miller units/mg of total cell protein. 
 
 
 
 
 
 
 
 
Table 2.8: Translational levels of DrrB after rare codon substitutions in DrrA. β-
Galactosidase activity of the fusion proteins encoded by indicated plasmids is shown on the right 
as percentage of Miller units/mg of total cell protein. 
 
 
 
 
 
 
 
 
 
 
 
 
 Construct Fusion protein Complemented with % 
1. pDx109 drrAdrrB::lacZ  100 
2. pDx109 drrAdrrB::lacZ pLysSRARE 100 
3. pDx109 drrAdrrB::lacZ pLysSRARE2 100 
4. pDx151 geneXdrrB::lacZ  973 
5. pDx151 geneXdrrB::lacZ pLysSRARE 960 
6. pDx151 geneXdrrB::lacZ pLysSRARE2 990 
 Construct Fusion protein % 
1. pDx109 drrAdrrB::lacZ 100 
2. pDx151 geneXdrrB::lacZ 973 
3. pDx170 drrA*drrB::lacZ (T320) 103 
4. pDx172 drrA**drrB::lacZ (T320, T289) 116 
5. pDx174 drrA****drrB::lacZ (T320, T289, P277, R278) 63 
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Table 2.9: Doxorubicin resistance of E.coli N43 cells expressing DrrAB proteins in 
DrrAΔ10aa, DrrAΔ10aaDrrB and glutamic acid (E) substitutions. N43 cells containing 
indicated plasmids were plated on M9 plates containing different concentrations of 
doxorubicin.  The plates were incubated at 37oC. Growth was scored after 24 hours of 
incubation.  Legend: +++, very good growth; ++, good growth; +, some growth; -, no growth. 
 
Amount of Dox, µg/ml Plasmid in N43 
No dox 4μg/ml 6 μg/ml 8μg/ml 10μg/ml 
Vector (pSU2718) +++ ++ - - - 
DrrA (pDx102) +++ - - - - 
DrrB (pDx203) +++ ++ - - - 
DrrAΔ10aa (pDx183) +++ - - - - 
DrrAB (pDx101) +++ +++ +++ ++ ++ 
DrrAΔ10aaDrrB (pDx200) +++ - - - - 
DrrA+DrrB (pDx102+pDx203) +++ - - - - 
DrrAΔ10aa+DrrB (pDx183+pDx203) +++ - - - - 
DrrAB(E321,322,325D) (pDx188) +++ - - - - 
DrrAB(E321,322,325G) (pDx186) +++ - - - - 
DrrAB(E321,322,325,326Q) (pDx190) +++ - - - - 
Legend: +++, very good growth; ++, good growth; +, some growth;-, no growth. 
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Fig.2.1: Expression of DrrB protein in the presence of its own RBS. E. coli cells containing 
the indicated plasmids were induced with IPTG.  The cells were lysed by French press, 
followed by ultracentrifugation at 100,000 × g for 1hr to prepare membrane fractions.  25 µg of 
membrane protein was analyzed by SDS-PAGE on 12% gels, followed by Western Blot 
analysis using anti-DrrA (Panel A) or anti-DrrB (Panel B) antibodies. Lane 1, vector 
(pSU2718); lane 2, DrrA (pDx102);  lane 3, DrrB (pDx103); lane 4, DrrAB (pDx101); lane 5, 
RBSDrrB (pDx153).   
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Fig.2.2: Schematic representation of the translational fusions of DrrB (pDx103 and 
pDx153) to β-galactosidase (pDx110 and pDx154) and their activities. The first 15 amino 
acids of the DrrB protein were fused to β-galactosidase as described under “Materials and 
Methods.” pDx110 and pDx154 are derived from pDx103 and pDx153, respectively. β-
Galactosidase activity of the fusion proteins encoded by pDx110 and pDx154 is shown on the 
right in Miller units/mg of total cell protein. 
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Fig.2.3: Effect of a mutation in the RBS on the expression of DrrB protein. E. coli cells 
containing the indicated plasmids were induced with IPTG.  The cells were lysed by French 
press, followed by ultracentrifugation at 100,000 × g for 1hr to prepare membrane fractions.  
25 µg of membrane protein was analyzed by SDS-PAGE on 12% gels, followed by Western 
Blot analysis using anti-DrrA (Panel A) or anti-DrrB (Panel B) antibodies. Lane 1, vector 
(pSU2718); lane 2, DrrA (pDx102);  lane 3, DrrB (pDx103); lane 4, DrrAB (pDx101); lane 5, 
DrrA + DrrB (pDx108 + pDx103) ; lane 6, DrrA-RBS*-DrrB (pDx148).   
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    I     II 
 
 
Fig.2.4: cDNA levels of drrA, drrB and geneX. I, Total bacterial RNA was isolated from E.coli 
containing the indicated plasmids. The RNA was subjected to reverse transcription to obtain 
cDNA. The cDNA was then analyzed on 0.8% agarose gel and stained with ethidium bromide. 
II, Table depicts the RNA template and the expected transcript obtained by use of specific 
combinations of primers.  
 
 
Lane
Nos. 
RNA 
template 
Transcript 
1. drrA+drrB drrA 
2. drrAB drrA 
3. geneXdrrB geneX 
4. drrB drrB 
5. drrA+drrB drrB 
6. drrAB drrB 
7. geneXdrrB drrB 
8. drrAB drrAB 
9. geneXdrrB geneXdrrB
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Fig.2.5: In vitro expression of DrrA and DrrB proteins using bacterial lysates (Ecopro). 
Two μg of plasmid DNA was transcribed and translated in a 50µl reaction by using bacterial 
lysates from Novagen. The newly synthesized proteins were labeled with L-[35S]Methionine. 
The reaction was carried out at 37°C for 1 hr. The translated proteins were then analyzed on 
SDS-PAGE, following which they were fixed by 10% tricholoracetic acid.  The gel was then 
dried and followed with autoradiography. Lane 1, vector (pET11a); lane 2, DrrA (pDx124); 
lane 3, DrrB (pDx113); lane 4, DrrA + DrrB (pDx124 + pDx113); lane 5, DrrAB (pDx139).   
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Fig. 2.6: In vitro expression of DrrAB with or without T7 tag at the N terminus of DrrA. 
Two μg of plasmid DNA was transcribed and translated in a 50µl reaction by using bacterial 
lysates from Novagen. The newly synthesized proteins were labeled with L-[35S]Methionine. 
The reaction was carried out at 37°C for 1 hr. The translated proteins were then analyzed on 
SDS-PAGE, following which they were fixed by 10% tricholoracetic acid.  The gel was then 
dried and followed with autoradiography. Lane 1, vector (pET11a); lane 2, DrrAB (pDx114); 
lane 3, DrrAB (pDx139).   
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Fig.2.7: In vitro expression of DrrAB proteins with rare codon substitutions (Ecopro). 
Two μg of plasmid DNA was transcribed and translated in a 50µl reaction by using bacterial 
lysates from Novagen. The newly synthesized proteins were labeled with L-[35S]Methionine. 
The reaction was carried out at 37°C for 1 hr. The translated proteins were then analyzed on 
SDS-PAGE, following which they were fixed by 10% tricholoracetic acid.  The gel was then 
dried and followed with autoradiography. Lane 1, vector (pET11a); lane 2, DrrA (pDx124); 
lane 3, DrrB (pDx113); lane 4, DrrAB (pDx139); lane 5, DrrAT320DrrB (pDx171) ; lane 6, 
DrrAT320, T289DrrB (pDx173) ; lane 7, DrrAT320, T289, P277, R278DrrB (pDx175). 
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Fig.2.8: In vitro expression of DrrA and DrrB proteins using rabbit lysates (STP3). I, 
Schematic representation of the clones pDx124 (drrA) and pDx145 (geneX). The clones 
contain plac and the RBS in front of the drrA or the geneX gene. GeneX contains the last 30 
bases of drrA. II, 0.5 μg of plasmid DNA was transcribed to obtain RNA using the STP3 
transcription mix at 30°C for 15 mins. The transcribed product was then translated using rabbit 
lysates (STP3) commercially obtained from Novagen.  The newly synthesized proteins were 
labeled with L-[35S]Methionine.  The translation reaction was carried out at 30°C for 1 hr.  The 
translated proteins were then analyzed on SDS-PAGE, following which they were fixed by 10 
% tricholoracetic acid.  The gel was then dried and followed with autoradiography. Lane 1, 
vector (pET11a); lane 2, DrrA (pDx124); lane 3, DrrB (pDx113); lane 4, DrrA + DrrB 
(pDx124 + pDx113); lane 5, DrrAB (pDx139) ; lane 6, GeneX (pDx145).   
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Fig.2.9: Comparison between in vivo species of DrrA and GeneX. E. coli cells containing 
the indicated plasmids were induced with IPTG.  The cells were lysed by French press, 
followed by ultracentrifugation at 100,000 × g for 1hr to prepare membrane fractions.  25 µg of 
membrane protein was analyzed by SDS-PAGE on 12% gels, followed by Western Blot 
analysis using anti-DrrA(C) (Panel A) or anti-DrrA (Panel B) antibodies. Lane 1, vector (pSU 
2718); lane 2, DrrA (pDx102); lane 3, DrrB (pDx103); lane 4, DrrA + DrrB (pDx108 + 
pDx103); lane 5, DrrAB (pDx101) ; lane 6, GeneXDrrB (pDx150) ; lane 7, GeneXDrrB + 
DrrA (pDx150 + pDx108).   
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Fig.2.10: Detection of 66 kDa species in cis conformations of DrrAB and GeneXDrrB by 
in vitro expression (Ecopro). Two μg of plasmid DNA was transcribed and translated in a 
50µl reaction by using bacterial lysates from Novagen. The newly synthesized proteins were 
labeled with L-[35S]Methionine. The reaction was carried out at 37°C for 1 hr. The translated 
proteins were then analyzed on SDS-PAGE, following which they were fixed by 10% 
tricholoracetic acid.  The gel was then dried and followed with autoradiography. Lane 1, vector 
(pET11a); lane 2, DrrA (pDx124); lane 3, DrrB (pDx113); lane 4, DrrA + DrrB (pDx124 + 
pDx113); lane 5, DrrAB (pDx139) ; lane 6, GeneX (pDx145) ; lane 7, DrrB (pDx113) ; lane 8, 
GeneX + DrrB (pDx145 + pDx113) ; lane 9, GeneXDrrB (pDx146).   
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pDx101: EEAAEEEKVA 
pDx188: DDAADEEKVA 
pDx186: GGAAGEEKVA 
pDx190: QQAAQQEKVA 
 
 
 
Fig.2.11: In vivo expression of DrrA and DrrB proteins containing substitutions of 
glutamic acid (E) residues. I, E. coli cells containing the indicated plasmids were induced 
with IPTG.  The cells were lysed by French press, followed by ultracentrifugation at 100,000 × 
g for 1hr to prepare membrane fractions.  25 µg of membrane protein was analyzed by SDS-
PAGE on 12% gels, followed by Western Blot analysis using anti-DrrA (Panel A) or anti-DrrB 
(Panel B) antibodies. Lane 1, vector (pSU2718); lane 2, DrrAB (pDx101); lane 3, E321, 322, 
325D (pDx188); lane 4, E321, 322, 325G (pDx186); lane 5, E321, 322, 325, 326Q (pDx190). 
II, Sequence indicating the various glutamic acid substitutions in drrA.  
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Fig.2.12: Expression of DrrA and DrrB proteins in DrrAΔ10aa and DrrAΔ10aaDrrB. I, 
Schematic representation of the clones pDx101 (drrAB), pDx183 (drrAΔ30bp) and pDx200 
(drrAΔ30bpdrrB). The last 30 base pairs of drrA have been deleted from the clones pDx183 
(drrAΔ30bp) and pDx200 (drrAΔ30bpdrrB). II, E. coli cells containing the indicated plasmids 
were induced with IPTG.  The cells were lysed by French press, followed by 
ultracentrifugation at 100,000 × g for 1hr to prepare membrane fractions.  25 µg of membrane 
protein was analyzed by SDS-PAGE on 12% gels, followed by Western Blot analysis using 
anti-DrrA (Panel A), anti-DrrB (Panel B) and anti-DrrA (C) (Panel C) antibodies. Lane 1, 
vector (pSU2718); lane 2, DrrA (pDx102); lane 3, DrrB (pDx103); lane 4, DrrA + DrrB 
(pDx108 + pDx103); lane 5, DrrAB (pDx101) ; lane 6, DrrAΔ10aa (pDx183) ; lane 7, 
DrrAΔ10aa +DrrB (pDx183 + pDx203) ; lane 8, DrrAΔ10aaDrrB (pDx200).   
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Fig.2.13: In vitro expression of DrrA containing glutamic acid (E) substitutions (Ecopro). 
Two μg of plasmid DNA was transcribed and translated in a 50µl reaction to using bacterial 
lysates from Novagen. The newly synthesized proteins were labeled with L-[35S]Methionine. The 
reaction was carried out at 37°C for 1 hr. The translated proteins were then analyzed on SDS-
PAGE, following which they were fixed by 10% tricholoracetic acid.  The gel was then dried and 
followed with autoradiography. Lane 1, vector (pET11a); lane 2, DrrA (pDx124); lane 3, DrrA + 
DrrB (pDX124 + pDx113) ; lane 4, DrrAB (pDx139) ; lane 5, E321, 322, 325D (pDx189); lane 
6, E321, 322, 325G (pDx187); lane 7, E321, 322, 325, 326Q (pDx191). 
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Fig.2.14: In vitro expression of DrrAΔ10aa and DrrAΔ10aaDrrB proteins (Ecopro). I, 
Schematic representation of the clones pDx139 (drrAB), pDx182 (drrAΔ30bp) and pDx205 
(drrAΔ30bpdrrB). The last 30 base pairs of drrA have been deleted from the clones pDx183 
(drrAΔ30bp) and pDx200 (drrAΔ30bpdrrB). II, Two μg of plasmid DNA was transcribed and 
translated in a 50 µl reaction to using bacterial lysates from Novagen. The newly synthesized 
proteins were labeled with L-[35S]Methionine. The reaction was carried out at 37°C for 1 hr. 
The translated proteins were then analyzed on SDS-PAGE, following which they were fixed by 
10% tricholoracetic acid.  The gel was then dried and followed with autoradiography. Lane 1, 
vector (pET11a); lane 2, DrrAB (pDx139); lane 3, DrrAΔ10aaDrrB (pDx205); lane 4, 
DrrAΔ10aa (pDx182) ; lane 5, DrrA (pDx124).   
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Fig.2.15: In vitro expression of DrrAB proteins containing spacers (Ecopro). I, Schematic 
representation of the clones pDx139 (drrAdrrB), pDx201 (drrA-17bp-drrB), pDx202 (drrA-
41bp-drrB) and pDx204 (drrA-68bp-drrB). The clones pDx197, pDx198 and pDx199 contain 
spacers of varying lengths between drrA and drrB. Two stop codons TAA and TAG have been 
inserted at the end of drrA of these clones. II, Two μg of plasmid DNA was transcribed and 
translated in a 50µl reaction to using bacterial lysates from Novagen. The newly synthesized 
proteins were labeled with L-[35S]Methionine. The reaction was carried out at 37°C for 1 hr. 
The translated proteins were then analyzed on SDS-PAGE, following which they were fixed by 
10% tricholoracetic acid.  The gel was then dried and followed with autoradiography. Lane 1, 
vector (pET11a); lane 2, DrrA (pDx124);  lane 3, DrrA + DrrB (pDx124 + pDx113); lane 4, 
DrrAB (pDx139); lane 5, DrrA-17bp-DrrB (pDx201) ; lane 6, DrrA-41bp-DrrB (pDx202) ;  
lane 7, DrrA-68bp-DrrB (pDx204).   
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Fig.2.16: Chemical crosslinking between DrrAS319C and DrrBS23C. I, Diagrammatic 
representation of DrrBS23C in the membrane. The serine to cysteine substitution is at the 23rd 
amino acid in DrrB. II, The cell membrane fractions were prepared and subjected to disulphide 
cross-linking using three different crosslinkers, as described under “Materials and Methods”.  
The reaction was terminated by the addition of 25 µL 4X non-reducing Laemmli sample buffer.  
50 µg of protein was resolved by SDS-PAGE using 10% gels followed by Western blot using 
anti-DrrA or anti-DrrB antibodies. Three cross-linkers of different am-lengths were used. Lane 1, 
No crosslinker; lane 2, 3 mM/9 mM CuPhe (0 Å); lane 3, 1 mM DTME (13.3 Å); lane 4, 0.2 mM 
MTS (24.0 Å). Cross-linked samples were probed with anti-DrrA or anti-DrrB antibodies.  The 
“minus” and “plus” at the bottom of the lanes indicate the absence and presence of the cross-
linker in the reaction, respectively.    
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DISCUSSION 
In the present work we have looked at some of the intrinsic factors that contribute to the 
biogenesis of the DrrAB drug efflux pump. DrrA, the peripheral membrane protein of the DrrAB 
system, contains the functional ATP binding domain, whereas the membrane component DrrB 
acts as a conduit for the transport of doxorubicin. In the drrAB operon stop codon of DrrA and 
start codon of DrrB overlap. This overlap suggested that the expression of DrrA was 
translationally coupled to that of DrrB. By introducing a stop codon within the coding sequence 
of drrA, it was confirmed that the expression of DrrB was indeed translationally coupled to 
DrrA. Translational coupling may act as an obligatory control in systems where the active RBS 
of the downstream gene is occluded within a stem loop structure which has high energy. The 
intergenic region between drrA and drrB was analyzed by the ‘mfold’ program for possible 
mRNA secondary structures. A stem loop structure was predicted to form in the intergenic 
region with a fairly high energy of ΔG = - 19.0 kcal/mol[12]. The RBS and start codon of DrrB 
lie embedded within this stem loop structure, which would therefore be unavailable for de novo 
initiation by free ribosomes. The translational dependence of drrB on drrA suggests that only 
those ribosomes primed to the translation of drrA have the capability to “open up” the stem loop 
structure and allow access to the RBS. These ribosomes primed to the synthesis of drrA will 
reinitiate translation of drrB or then allow free ribosomes to carry out de novo synthesis. The 
most interesting upshot of the coupling was the formation of a functional complex only in the 
presence of the overlap between the stop codon of drrA and start codon of drrB (ATGA). The 
proteins could be maintained in a cis configuration by insertion of spacers yet spatial proximity 
was found to be crucial for proper folding of the two proteins. The main conclusion from this 
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study was that the intrinsic coupling between the drrA and drrB genes acts as an important factor 
in functional complex formation. 
Exciting observations from the first study lead us into the next Chapter. In the first study 
it was seen that the expression of DrrB could be coupled to any upstream ORF. On coupling 
drrB to another gene(X), a drastic ten fold increase in expression of DrrB was observed. The 
chimeric sequence of geneX contained the last 30 base pairs of drrA within which the RBS of 
drrB is embedded. LacZ and expression analysis of various constructs showed that this RBS was 
indeed active and it was essential for expression of DrrB. The difference in expression of DrrB 
between the two coupled systems; drrAB and geneXdrrB suggested that there is an inherent 
mechanism within drrA which controls the levels of DrrB to optimal levels. To understand how 
this control is regulated in the DrrAB system several mechanisms were scrutinized. Rare codons 
have been suggested to reduce expression of genes in heterologous systems[18]. By 
complementation with tRNA genes expressing rare codons on a compatible plasmid the chance 
of reduced expression of DrrB in DrrAB due to rare codons was ruled out. RT-PCR analysis 
overruled differential mRNA levels as a possible mechanism of controlling DrrB levels[37]. In 
vitro translation analysis hinted at an autogenous control in translation of DrrA probably at the C 
terminus. Analysis of the C terminus of DrrA revealed a rather unique sequence; 
EEAAEEEKVA which contained high frequency of negatively charged glutamic acid residues. 
This sequence which is shared by both DrrA and the chimeric protein GeneX was found to be 
involved in formation of complex. In vivo functional studies showed that the C terminus of DrrA 
was indispensable for complex formation and the glutamic acid residues were essential for 
function. Cysteine crosslinking analysis confirmed that the C terminus of DrrA is indeed 
involved in the complex formation of DrrAB. 
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Based on the data presented in this study a model is proposed for the biogenesis of the 
DrrAB drug pump.  DrrA and DrrB form a functional complex only when the genes are in cis 
configuration.  The DrrA and DrrB proteins translated from different plasmids in trans can 
stabilize each other via an interaction unlike that in cis.  Although the proteins are thus stably 
maintained in the cell this complex is unable to carry out transport of doxorubicin. In the cis 
conformation, drrAB were found to co-transcribe and DrrB was found to be dependent on DrrA 
for its expression via translational coupling. An assembly domain (EEAAEEEKVA) was 
predicted in this study was found to lie in the C terminus of DrrA. Only the fully translated DrrA 
protein forms a complex with the N terminus of DrrB.  Two possibilities are that either the DrrA 
and DrrB proteins complex in the vicinity of the membrane and are then targeted into the 
membrane as a complex, or that DrrB is first targeted into the membrane and then it complexes 
with DrrA to form a functionally assembled transporter. The formation of a functional complex 
may act as a feedback trigger for the regulation of translation in DrrA. The last 30 nucleotides of 
the mRNA of drrA might then interact with unknown upstream sequences of drrA to cause 
translational arrest at the C terminus of DrrA. Since DrrB is translationally coupled to drrA this 
translational arrest in conjunction with coupling will cause lowering in the levels of DrrB. This 
model is expected to serve as primer and open up an interesting yet insufficiently understood 
subject of membrane protein biogenesis.  
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Fig.D-1: A model for the assembly of DrrA and DrrB proteins 
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